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Abstract
Cardiovascular complications are the leading cause of death in patients with chronic
kidney disease (CKD). The uraemic heart is characterised by cellular and structural
remodelling, including left ventricular hypertrophy (LVH), which contribute to heart
failure. Erythropoietin (EPO) has revolutionised the treatment of the anaemia
associated with CKD. The discovery that the EPO receptor is also expressed on
cardiomyocytes highlights a role of EPO beyond haematopoiesis. However, little is
known on the cellular impact of EPO on the uraemic heart. The aim of this study
was to determine the effect of EPO administration on uraemic cardiomyopathy.
Uraemia was induced surgically in male Sprague-Dawley rats via a subtotal
nephrectomy and animals retained for 3, 6, 9 or 12 weeks post-surgery. EPO was
administered subcutaneously twice a week for 2 weeks prior to sacrifice at a dose
of 30 µg/Kg. Cardiac function was assessed in vitro in the perfused heart and in vivo
using an arterial pressure catheter. Cardiac metabolism was analysed using 13C
NMR along with the activity and protein expression of key metabolic enzymes. In a
separate set of experiments, mitochondrial function was determined in vitro using
an oxygen electrode. To determine the extent of cardiac fibrosis, collagen was
stained using picro-sirius red in frozen sections.
Kidney dysfunction was observed from 3 weeks post-surgery as evident by
significantly raised serum creatinine and urea, and development of anaemia. LVH
was present at 6 and 12 weeks post-induction of uraemia, however in vitro and in
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vivo cardiac function was preserved, highlighting a compensatory phase. EPO did
not impact on renal function, however, EPO significantly improved haematocrit and
induced regression of LVH in uraemic animals at 12 weeks. In addition to preserved
cardiac function, myocardial mitochondrial respiration was not modified by
uraemia and unaffected by EPO administration. There was a decrease in palmitate
utilisation in uraemic hearts compared to controls at 6 weeks post-surgery despite
the unchanged activities of key metabolic enzymes including citrate synthase,
medium chain acyl-CoA dehydrogenase and pyruvate dehydrogenase activity.
Furthermore, the protein expression of CD36 and PPARα was the same in uraemic
and control hearts. At 12 weeks post-surgery, uraemic animals exhibited
significantly increased collagen within the heart compared to controls, highlighting
cardiac fibrosis.
In summary, by 12 weeks post-induction of uraemia, animals exhibited impaired
kidney dysfunction, LVH, metabolic remodelling and cardiac fibrosis with preserved
cardiac and mitochondrial function. Further work is required to determine whether
the structural and metabolic remodelling which accompany uraemic
cardiomyopathy would lead to a deterioration in cardiac function with prolonged
uraemia.
iii | P a g e
Acknowledgments
I am extremely grateful to my supervisor, Dr Anne-Marie Seymour, for her
guidance, encouragement and patience throughout my PhD. In particular, I would
like to thank Dr Seymour for her time and supervision when writing the thesis. I am
also thankful to my second supervisor, Dr Sunil Bhandari for the support he has
provided throughout my PhD and guidance writing the thesis.
I would like to thank Mrs Jenny Foster and Mrs Kathleen Bulmer for their invaluable
technical support. In particular, I am grateful to Kath for her assistance with the
western blotting and Dr Yong Wang for his help with the in vivo pressure
measurements. I also wish to thank Mrs Ann Lowry for her guidance on the
histological techniques and Dr Chee-Kay Cheung for the kidney images.
I would like to dedicate this thesis in memory of my dad, who supported and
encouraged me throughout my education. I am also indebted to my mum and
sister; without their strength and support over the last three years, this thesis
would not have been possible.
My sincere gratitude also goes to my partner Mark, friends and family for their
encouragement during my PhD. I should also like to thank my colleagues and
friends at the University, David Semple, Dunja Aksentijevic and Thomas Butler.
Finally, I am grateful for to the British Heart Foundation for funding this PhD. This
work has funded by a BHF studentship, grant number FS/06/047.
Contents
Abstract
Acknowledgments
Contents
Figure List
Table List
Abbreviations
Chapter 1: Introduction
1.1 Chronic Kidney Disease (CKD)
1.2 Myocardial Calcium Handling
1.3 Left Ventricular Hypertrophy (LVH)
1.3.1 Metabolic Remodelling in LVH
1.4 Capillary Abnormalities
1.5 Cardiac Fibrosis
1.5.1 Extracellular Matrix (ECM)
1.6 Erythropoietin (EPO)
1.6.1 Biochemistry of EPO and EPO Receptor
1.6.2 Cardiovascular Effects of EPO
1.6.2.1 Acute Cardioprotective Effects
1.6.2.2 Chronic Cardioprotective Effects
1.7 Objectives
Chapter 2: Materials and Methods
2.1 Materials
2.2 Methods
2.2.1 Induction of Uraemia
2.2.2 Preparation of Krebs-Hensleit (K-H) Buffer
2.2.3 Preparation of Bovine Serum Albumin (BSA)
2.2.4 Heart Perfusion
2.2.4.1 Pacing
2.2.4.2 In Vitro Cardiac Function
2.2.4.3 Oxygen Consumption (MVO2)
2.2.4.4 Indices of Hypertrophy
2.2.4.5 Haematocrit and Serum Analysis
2.2.5 13C NMR Spectroscopy
2.2.5.1 Perchloric Acid (PCA) Tissue Extraction
2.2.5.2 Preparation of NMR samplesPageiv | P a g e
i-ii
iii
iv-vii
viii-ix
x
xi-xii
1
2
4
7
9
12
15
15
18
19
21
23
27
29
31
32
35
35
36
37
38
40
41
43
45
45
45
45
46
v | P a g e
2.2.5.3 Acquisition of 13C Spectra 46
2.2.5.4 13C Labelling Profiles 47
2.2.6 Biochemical Assays 53
2.2.6.1 Pyruvate Dehydrogenase (PDH) Assay 53
2.2.6.2 Citrate Synthase (CS) Assay 56
2.2.6.3 Medium chain Acyl Co-A dehydrogenase (MCAD) Assay 56
2.2.6.3.1 Preparation of Ferricene Salt 56
2.2.6.3.2 MCAD Assay 57
2.2.7 In Vitro Mitochondrial Function 57
2.2.7.1 Isolation of Mitochondria 57
2.2.7.2 Mitochondrial Respiration 58
2.2.8 Western Blotting 60
2.2.8.1 Preparation of Samples 60
2.2.8.2 SDS- Page and Western Blotting 61
2.2.8.3 Visualisation and Quantification 61
2.3 Statistical Analysis 63
Chapter 3: Characterisation of the Experimental Model 64
3.1 Introduction 65
3.1.1 Experimental Models of CKD 65
3.1.2 Erythropoietin Treatment 68
3.1.3 Objectives 70
3.2 Materials and Methods 71
3.2.1 Induction of Uraemia 71
3.2.2 Erythropoietin Treatment 71
3.2.3 Biochemical Analysis and Determination of LVH 72
3.2.4 In Vivo Haemodynamic Analysis 73
3.3 Results 75
3.3.1 Degree of Uraemia 75
3.3.2 In Vivo Blood Pressure 84
3.3.3 Indices of LVH 87
3.4 Discussion 94
3.4.1 Experimental Model of CKD 94
3.4.2 Blood Pressure 96
3.4.3 LVH 98
3.4.4 EPO Treatment 100
3.4.5 Conclusions 101
Chapter 4: In Vitro Cardiac Function and Metabolism 102
4.1 Introduction 103
vi | P a g e
4.1.1 Determination of In Vitro Cardiac Function 103
4.1.2 Metabolic Remodelling 104
4.1.3 Objectives 106
4.2 Materials and Methods 108
4.2.1 Effects of Acute EPO Administration 108
4.2.2 Effects of Uraemia and Chronic EPO Administration 108
4.2.3 Mitochondrial Enzyme Activities 109
4.3 Results 111
4.3.1 Effects of Acute EPO Administration 111
4.3.2 Effects of Uraemia and Chronic EPO Administration 112
4.3.3 Cardiac Metabolism 121
4.3.4 Mitochondrial Enzyme Activities 124
4.4 Discussion 127
4.4.1 Effects of Acute EPO Administration 127
4.4.2 Effects of Uraemia and Chronic EPO Administration 128
4.4.3 Myocardial Metabolism 130
4.4.4 Conclusion 133
Chapter 5: In Vivo Cardiac Function and Fibrosis 135
5.1 Introduction 136
5.1.1 Cardiac Fibrosis 136
5.1.2 In Vivo Cardiac Function 139
5.1.3 Objectives 140
5.2 Methods 141
5.2.1 Induction of Uraemia and EPO treatment 141
5.2.2 Determination of In Vivo Cardiac Function 141
5.2.3 Histology of Uraemic Hearts 142
5.3 Results 146
5.3.1 In Vivo Cardiac Function 146
5.3.2 Cardiac Fibrosis 149
5.4 Discussion 154
5.4.1 In Vivo Cardiac Function 154
5.4.2 Cardiac Fibrosis 156
5.4.2.1 The Impact of EPO on Cardiac Fibrosis 160
5.4.3 Conclusions 161
Chapter 6: Mitochondrial Function and Protein Expression 163
6.1 Introduction 164
6.1.1 Electron Transport Chain (ETC) 164
vii | P a g e
6.1.2 Reactive Oxygen Species (ROS) Production 166
6.1.3 Mitochondrial Function in Uraemia 168
6.1.4 Objectives 169
6.2 Methods 170
6.2.1 Mitochondrial Respiration 170
6.2.2 Protein Expression 172
6.3 Results 173
6.3.1 Mitochondrial Respiration 173
6.3.2 Metabolic Protein Expression 181
6.4 Discussion 183
6.4.1 Mitochondrial Respiration 183
6.4.2 Metabolic Protein Expression 188
6.4.2.1 Impact of EPO on Protein Expression 189
6.4.3 Conclusions 190
Chapter 7: Discussion and Future Work 191
7.1 Discussion 192
7.1.1 Extent of Kidney Dysfunction 192
7.1.2 EPO Treatment 194
7.2 Future Work 196
Publications 201
References 202-226
viii | P a g e
Figure List
Chapter 1: Introduction
1.1 Myocardial calcium handling 5
1.2 Schematic diagram of eccentric and concentric LVH 8
1.3 Myocardial substrate metabolism 9
1.4 PPARα activation 11
1.5 Diagram showing the sequence of events leading to heart
failure in uraemia
14
1.6 Diagram of extracellular matrix distribution in muscle 16
1.7 Schematic diagram of EPO signalling 20
1.8 Apoptosis pathway 54
Chapter 2: Materials and Methods
2.1 Isovolumic Langendorff perfusion apparatus 39
2.2 Isolated perfused rat heart 40
2.3 Recording of cardiac function 42
2.4 Recording of cardiac contractility 43
2.5 a) Profile following 1-13C glucose
b) Profile following U-13C palmitate
49
50
2.6 13C NMR spectra showing expansion of resonances of
glutamate
51
2.7 Recording showing oxygen consumption of isolated
mitochondria
59
Chapter 3: Characterisation of the Experimental Model
3.1 Experimental protocol 72
3.2 Diagram of positioning of catheter 73
3.3 Serum biochemistry 76
3.4 Haematocrit 12 weeks post-induction of uraemia 78
3.5 Spleen weight at 3, 6, 9 and 12 weeks uraemia 80
3.6 Water content of lungs 83
3.7 Systolic and diastolic blood pressures at 12 weeks post-
induction of uraemia
85
3.8 Indices of LVH at 12 weeks post-induction of uraemia 91
3.9 Correlation between haematocrit and extent of LVH 92
3.10 Correlation between serum creatinine and extent of LVH 92
3.11 Correlation between systolic blood pressure and extent of LVH 93
ix | P a g e
Chapter 4: In Vitro Cardiac Function and Metabolism
4.1 Perfusion protocols 110
4.2 Rate pressure product at 3 weeks post-induction of uraemia 113
4.3 MVO2 at 3 weeks post-induction of uraemia 113
4.4 Cardiac efficiency in uraemia 114
4.5 Rate pressure product at 6 weeks post-induction of uraemia 117
4.6 MVO2 at 6 weeks post-induction of uraemia 117
4.7 Rate pressure product at 12 weeks post-induction of uraemia 120
4.8 MVO2 at 12 weeks post-induction of uraemia 120
4.9 Contribution of 13C substrates to oxidative metabolism in
uraemia
122-123
4.10 MCAD activity at 3 weeks post-induction of uraemia 125
4.11 MCAD activity at 12 weeks post-induction of uraemia 125
4.12 PDH activity at 12 weeks post-induction of uraemia 126
Chapter 5: In Vivo Cardiac Function and Fibrosis
5.1 Recording of in vivo function 142
5.2 Sequence of collagen quantification (using ImageJ software) 145
5.3 In vivo cardiac contractility at 12 weeks post-induction of
uraemia
148
5.4 Cardiac tissue stained using picro-sirius red 150
5.5 Quantification of cardiac fibrosis at 12 weeks uraemia 151
5.6 Sections from uraemic hearts showing types of fibrosis 152
5.7 Cardiac tissue stained using Haematoxylin and Eosin 153
Chapter 6: Mitochondrial Function and Protein Expression
6.1 Schematic representation of the electron transport chain (ETC) 165
6.2 Mitochondrial ROS generation and induction of apoptosis 167
6.3 Clark- type Electrode 171
6.4 Myocardial mitochondrial respiration using complex I substrates 174
6.5 State 3 respiration in the presence of rotenone 175
6.6 Myocardial respiration rates using complex I substrates at 12
weeks uraemia
180
6.7 Cardiac PPARα protein expression at 12 weeks uraemia 182
6.8 Cardiac CD36 protein expression at 12 weeks uraemia 182
Chapter 7: Discussion and Future Work
7.1 Kidney section stained with Masson’s trichrome stain 194
7.2 Recovery of rate pressure product (RPP) during reperfusion 198
x | P a g e
Table List
Chapter 1: Introduction
1.1 Classification of the cardio-renal syndrome 3
1.2 Factors involved in the pathophysiological cardiac phenotype in
CKD
4
Chapter 2: Materials and Methods
2.1 Materials and Suppliers 32
2.2 Components of PDHt and PDHa homogenisation buffers 54
2.3 Antibody dilutions and suppliers 62
Chapter 3: Characterisation of the Experimental Model
3.1 Haematocrit 78
3.2 Left kidney weights 81
3.3 In vivo blood pressure at 12 weeks post-induction of uraemia 86
3.4 Measurement of LVH during progression of uraemia 89-90
Chapter 4: In Vitro Cardiac Function and Metabolism
4.1 Effects of acute EPO administration 111
4.2 In Vitro cardiac function at 3 weeks uraemia 112
4.3 In Vitro cardiac function at 6 weeks uraemia 116
4.4 In Vitro cardiac function at 12 weeks uraemia 119
4.5 Citrate Synthase (CS) activity at 6 and 12 week post-induction of
uraemia
124
Chapter 5: In Vivo Cardiac Function and Fibrosis
5.1 In vivo cardiac function at 12 weeks post-induction of uraemia 147
Chapter 6: Mitochondrial Function and Protein Expression
6.1 Myocardial mitochondrial yields at 12 weeks uraemia 174
6.2 Mitochondrial respiration at 9 weeks post-induction of uraemia
using complex I and complex II substrates
177
6.3 Mitochondrial respiration at 12 weeks post-induction of uraemia
using complex I and complex II substrates
178-179
xi | P a g e
Abbreviations
ACE............................ Angiotensin Converting Enzyme
ACEi........................... Angiotensin Converting Enzyme Inhibitor
ATP…………………………. Adenosine Triphosphate
bpm........................... beats per minute
CEPO………………………. Carbamylated Erythropoietin
CHF………………………… Chronic Heart Failure
CKD………………………… Chronic Kidney Disease
CPT………………………… Carnitine Palmitoyltransferase
CRS........................... Cardio-renal Syndrome
CS.............................. Citrate Synthase
DCA........................... Dichloroacetic acid
DP………………………….. Diastolic Pressure
DTT........................... Dithiothreitol
ECC………………………… Excitation-Contraction Coupling
EDP........................... End Diastolic Pressure
EDTA........................ Ethylenediaminetetraacetic acid
EPC………………………… Erythroid Progenitor Cell
EPO………………………… Erythropoietin
EPOR………………………. Erythropoietin Receptor
ER.............................. Endoplasmic Reticulum
ESRD………………………. End Stage Renal Disease
ETC............................ Electron Transport Chain
FA………………………….. Fatty Acid
FAD........................... flavin-adenine dinucleotide
FAO………………………… Fatty Acid Oxidation
FAT…………………………. Fatty Acid Translocase
FATP……………………….. Fatty Acid Transport Protein
G-6-P………………………. Glucose-6-Phospahte
GFR............................ Glomerular Filtration Rate
GSK3-β...................... Glycogen Synthase Kinase 3-β
HCM.......................... Hypertrophic Cardiomyopathy
HF…………………………... Heart Failure
HIF-1 α………………...... Hypoxia Inducible Factor 1 α
HR………………………….. Heart Rate
ip……………………………. Intra- Peritoneal
KH.............................. Krebs Hensleit (Buffer)
LV…………………………... Left Ventricle
xii | P a g e
LVDP………………………. Left Ventricular Developed Pressure
LVH………………….…….. Left Ventricular Hypertrophy
MAP........................... Mean arterial pressure
MAPK……………………… Mitogen Activated Protein Kinase
MCAD........................ Medium- Chain Acyl Co-A Dehydrogenase
MI…………………………… Myocardial Infarction
MMP………………………. Matrix Metalloproteinase
MPTP........................ Mitochondrial Permeability Transition Pore
NMR………………………. Nuclear Magnetic Resonance
NAD.......................... Nicotinamide Adenine dinucleotide
NADPH...................... Nicotinamide Adenine dinucleotide phosphate oxidase
NCX……………………….. Sodium-Calcium Exchanger
NO………………………….. Nitric Oxide
NOS………………………… Nitric Oxide Synthase
PCA........................... Perchloric acid
PCr............................ Phosphocreatine
PDH………………………… Pyruvate Dehydrogenase
PGC1α....................... PPARγ coactivator-1 α
PI3K………………………… Phosphatidylinositol 3-kinase
PKC…………………………. Protein Kinase C
PLB…………………………. Phospholamban
PPAR α……………………. Peroxisome Proliferator-Activated Receptor α
PPRE……………………….. Peroxisome Proliferator Response Element
RAAS.......................... Renin-Angiotensin-Aldosterone System
RBC………………………… Red Blood Cell
rhEPO……………………… Recombinant (Human) Erythropoietin
ROS………………………… Reactive Oxygen Species
RPP…………………………. Rate Pressure Product
RXR………………………… Retinoid X Receptor
RyR…………………………. Ryanodine Receptor
s/c…………………………… Subcutaneous
SNS………………….……... Sympathetic Nervous System
SERCA…………………….. Sarco(endo)plasmic reticulum Ca2+-ATPase
SHR........................... Spontaneously Hypertensive Rat
SP…………………………… Systolic Pressure
SR…………………………… Sarcoplasmic Reticulum
TCA cycle.................. Tricarboxylic acid cycle
TNF α……………………… Tumour Necrosis Factor α
UCP........................... Uncoupling Protein
VEGF………………………. Vascular Endothelial Growth Factor
1 | P a g e
Chapter 1: Introduction
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1.1 Chronic Kidney Disease
Cardiovascular complications remain the leading cause of mortality in patients with
chronic kidney disease (CKD), accounting for approximately 50% of all deaths
(USRDS 1998). Cardiac risk is increased 10-20 times in uraemic patients compared
with the aged matched general population (Raine et al., 1992, Foley et al., 1998). In
contrast to the general population, the relative importance of arteriosclerotic
disease is diminished and those of left ventricular hypertrophy (LVH), heart failure
and sudden cardiac death, increased in patients with CKD (Foley et al., 2003).
The coexistence of CKD and cardiac complications, known as the cardio-renal
syndrome (CRS), creates a cardiac phenotype unique to the uraemic heart,
described as uraemic cardiomyopathy. Recently, a new system for the classification
of the cardio-renal syndrome has been proposed, based on the duration and
sequence of organ dysfunction (Ronco et al., 2008) (table 1.1).
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Table 1.1: Classification of the cardio-renal syndrome (Ronco et al., 2008)
CRS Type I (Acute Cardio-renal Syndrome)
Abrupt worsening of cardiac function (e.g. acute cardiogenic shock or acutely
decompensated congestive heart failure) leading to acute kidney injury
CRS Type II (Chronic Cardio-renal Syndrome)
Chronic abnormalities in cardiac function (e.g. chronic congestive heart
failure) causing progressive and potentially permanent chronic kidney disease
CRS Type III (Acute Reno-cardiac Syndrome)
Abrupt worsening of renal function (e.g. acute kidney ischaemia or
glomerulonephritis) causing acute cardiac disorder (e.g. heart failure,
arrhythmia, ischemia)
CRS Type IV (Chronic Reno-cardiac Syndrome)
Chronic kidney disease (e.g. chronic glomerular or interstitial disease)
contributing to decreased cardiac function, cardiac hypertrophy and/or
increased risk of adverse cardiovascular events
CRS Type V (Secondary Cardio-renal Syndrome)
Systemic condition (e.g. diabetes mellitus, sepsis) causing both cardiac and
renal dysfunction
The pathogenesis of uraemic cardiomyopathy is complex and incompletely
understood. However, the association and persistence of haemodynamic factors,
including anaemia and hypertension, in addition to metabolic and endocrine
abnormalities, contribute to the pathophysiological cardiac phenotype observed in
patients with CKD (table 1.2).
4 | P a g e
Table 1.2: Factors involved in the pathophysiological cardiac phenotype in CKD
Cardiac Risk Factors in Uraemia
 Anaemia
 LV hypertrophy
 Volume overload
 Hypertension
 Insulin resistance
 Diabetes
 Oxidative stress
 Chronic inflammation
 Secondary and tertiary
hyperparathyroidism
 Uraemic toxins
 Hypoalbuminaemia
 Hyperhomocysteinaemia
The uraemic heart is characterised by complex cellular and structural remodelling,
including altered calcium handling, LVH, reduced capillary density and cardiac
fibrosis, which contribute to the development of heart failure (HF) and reduced
survival in CKD patients (Amann et al., 1998a, Gross and Ritz, 2008).
1.2 Myocardial Calcium Handling
Altered calcium homeostasis is central to the progression of cardiac dysfunction
and failure (Bers et al., 2006). Indeed, experimental studies show that abnormal
calcium handling causes depressed contractility and cardiac dysfunction in LVH
(Houser and Margulies 2003).
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In the normal heart, Ca2+ transients stimulate muscle contraction in a process
known as excitation-contraction coupling (ECC) (Figure 1.1). During membrane
depolarisation, Ca2+ enters the cell via the T-tubules using voltage dependent L-type
Ca2+ channels. This triggers an amplification response through Ca2+ release from the
sarcoplasmic reticulum (SR) via the ryanodine receptor (RyR), known as calcium-
induced calcium release (Fabiato and Fabiato, 1979). In turn, Ca2+i binds to troponin
Figure 1.1: Myocardial calcium handling
(adapted from Maier and Bers 2007)
NCX sodium calcium exchanger; RyR ryanodine receptor; SERCA sarco(endo)plasmic
reticulum Ca2+-ATPase; PLB phospholamban; SR sarcoplasmic reticulum
6 | P a g e
C on the thin filaments, causing a conformational change and liberating the actin
site to interact with myosin (Bers, 2002). This process leads to cross bridge cycling
and muscle contraction. Dissociation of Ca2+ from troponin C initiates relaxation.
Ca2+ is predominantly removed from the cytosol by the phospholamban-regulated
sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA), and to a lesser extent the Na+
/Ca2+ exchanger (NCX) (Hasenfuss and Pieske, 2002, Yano et al., 2005) (Figure 1.1).
Altered expression of the key regulatory proteins involved in calcium homeostasis
contributes to LV dysfunction and failure (Hasenfuss, 1998). In the failing heart,
intracellular Ca2+ transients are decreased, in part due to a reduction in L-type Ca2+
channel density (Litwin et al., 2000). A decrease in SR Ca2+ content could also
contribute to the diminished calcium transient, possibly as a result of the
hyperphosphorylation of RyR causing an increased diastolic SR Ca2+ leak (Marx et
al., 2000). Removal of Ca2+ from the cytosol may also be impaired during heart
failure. Indeed, reductions in SERCA expression have been observed in both
experimental (Feldman et al., 1993) and clinical heart failure studies (Hasenfuss,
1998). Furthermore, prolonged calcium transients, highlighting delayed relaxation,
have also been observed in the uraemic rat heart (McMahon et al., 2002). SERCA is
regulated by phospholamban (PLB). In the dephosphorylated state, PLB exerts an
inhibitory effect on SERCA activity. Ca2+-calmodulin-dependent or c-AMP
dependent protein kinases phosphorylate PLB, thereby relieving SERCA inhibition (Ji
et al., 2003, Schwinger et al., 1999). Although PLB expression remains unchanged in
HF, phosphorylation is reduced, resulting in a greater inhibitory effect on SERCA
(Schwinger et al., 1999). Abnormalities in Ca2+ regulatory proteins may contribute
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to dyssynchronous Ca2+ release and alterations in myocyte contractility. Thus,
correcting these abnormalities may provide an attractive therapeutic target for
reversing LV dysfunction in the uraemic heart.
1.3 Left Ventricular Hypertrophy (LVH)
LVH is the most common cardiac adaptation in CKD, present in up to 75% of
haemodialysis patients, primarily due to salt and water retention, anaemia and
hypertension although metabolic and endocrine abnormalities play a role (Foley et
al., 1995). LVH is also observed in patients with modest renal insufficiency and is a
powerful independent predictor of survival in these patients (Silberberg et al., 1989,
Levin et al., 1999, Ritz and McClellan, 2004).
Cardiomyocytes are terminally differentiated at birth and therefore hypertrophy is
the primary adaptive response to a variety of physiological and pathological
stresses rather than hyperplasia (Meerson, 1971). Indeed, the enlargement of
individual cardiomyocytes helps to normalise wall tension and maintain systolic
function (Grossman, 1980). However, clinical studies have shown that
hypertrophied hearts are more susceptible to injury and ventricular dysfunction
(Maron et al., 2000). Furthermore, epidemiological studies show that LVH may
initiate a cascade of detrimental changes, ultimately resulting in heart failure (Levy
et al., 1990). This would suggest that the initial hypertrophic response is beneficial
but its progression leads to many of the adaptations becoming limiting and thus
maladaptive, contributing to deterioration of cardiac function and onset of heart
failure (Meerson, 1971)
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be classified into two distinct phenotypes, eccentric and concentric
hy (Figure 1.2). Eccentric hypertrophy is caused by volume overload. In
ario, new sarcomeres are added in series, which results in ventricular
In contrast, pressure overload leads to thickening of the ventricular wall,
s concentric hypertrophy, and occurs due to the addition of new
es in parallel to existing sarcomeres.
ective study, Parfrey et al (1996) found that eccentric LVH was present in
concentric LVH in 40% of patients commencing haemodialysis therapy,
om increased preload (e.g. anaemia and hypervolaemia) and increased
(e.g. hypertension and aortic stiffening) respectively (Parfrey et al., 1996,
l., 1995).
Figure 1.2: Schematic diagram of eccentric and concentric LVH
1.3.1 Metabolic Remodelling in LVH
Hypertrophy per se is associated with cellular remodelling, with strong evidence of
altered energy provision (Ingwall, 2009). The heart is reliant upon a continuous
supply of oxygen and nutrients to meet the high demands of myocardial tissue and
maintain contractile function. Figure 1.3 summarises the pathways involved in
myocardial substrate metabolism. Under normal conditions, the heart derives 60%-
90% of its energy from fatty acid oxidation (FAO), with the remaining contribution
predominantly from glucose and lactate oxidation (Salem et al., 2002, Stanley et al.,
2005).Figure 1.3: Myocardial substrate metabolism9 | P a g e
(taken from Stanley et al., 2005)
10 | P a g e
Fatty acids enter the cell using the FATP and FAT/CD36 transporters and are
activated to acyl-CoA via esterification by ATP and acyl-CoA synthetase.
Subsequently, the carnitine shuttle, (consisting of carnitine palmitoyl transferase-1
(CPT-1), carnitine acyl transferase and carnitine palmitoyl transferase-2 (CPT-2)),
transports acyl-CoA into the mitochondrial matrix (Figure 1.3). Oxidation of fatty
acids produces acetyl-CoA, which can then enter the tri-carboxylic acid (TCA) cycle.
β-oxidation also generates NADH and FADH2, which drive the electron transport
chain and consequently ATP production (Finck and Kelly, 2002, Stanley and
Chandler, 2002).
In contrast, glucose enters the cell using the glucose transporters, GLUT1 and
GLUT4, the insulin-dependent transporter. In the cytosol, glucose undergoes
glycolysis to form pyruvate. Pyruvate is either converted to lactate, or transported
into the mitochondria and converted into acetyl-CoA via pyruvate dehydrogenase
(PDH) (Sambandam et al., 2002) (Figure 1.3). Under normal conditions, glycolysis
accounts for 5-10% of the total ATP production in the heart (Allard et al., 1994,
Lopaschuk, 2002).
Experimental models of LVH have shown a decrease in FAO and an enhanced
reliance on carbohydrate utilisation, in particular glucose, consistent with a re-
expression of the foetal gene programme (Allard et al., 1994, Nascimben et al.,
2004, Akki et al., 2008, Seymour, 2003b). The foetus relies on glucose for ATP
production; after birth, the up-regulation of FAO parallels mitochondrial
development and an increased expression of the regulatory transcription factor,
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peroxisome proliferator-activated receptor α (PPARα) (Barger and Kelly, 2000).
PPARα interacts with the heterodimeric receptor, RXR (retinoid X receptor), which
together, bind to the consensus DNA sequence known as the peroxisome
proliferator response element (PPRE) (Figure 1.4). Gene transcription is initiated
upon activation of the complex by the co-factor PGC-1 (PPARγ coactivator-1 α).
nucleus
FAO gene
transcription
FAO enzymes
Figure 1.4: PPARα activation
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During hypertrophy, expression of PPARα is reduced, coinciding with a lowering of
the expression of FAO enzymes, including CPT1 and medium chain acyl CoA
dehydrogenase (MCAD) (Barger et al., 2000). Although the shift towards glucose
utilisation may be initially beneficial in terms of oxygen efficiency (Taegtmeyer,
1986), the change in metabolic profile may, in the longer term, result in
complications, including accumulation of lipids and energy depletion (Lehman and
Kelly, 2002, Leone et al., 1999, Neubauer, 2007). Specifically, the build up of fatty
acyl components, due to reduced oxidation of lipids, results in sequestration of CoA
and therefore a reduction in the CoA to acetyl-CoA ratio. This may subsequently
cause an inhibition of pyruvate dehydrogenase, the rate limiting step in the entry of
glucose in to the TCA cycle, thus resulting in a limited capacity to utilise both fatty
acids and glucose (Russell and Taegtmeyer, 1992, Seymour and Chatham, 1997,
Seymour, 2003b).
1.4 Capillary Abnormalities
In experimental models of CKD, and in the clinical setting, it has been shown that
capillary growth does not keep pace with cardiomyocyte hypertrophy (Amann et
al., 1998a, Amann et al., 1992). Interestingly, the decrease in capillary to myocyte
ratio was not observed in an experimental model of essential hypertension,
suggesting that this characteristic is specific to uraemic cardiomyopathy, a feature
specifically of cardiac rather than muscle in general (Amann et al., 1997).
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A reduction in capillary density leads to a greater diffusion distance from the
capillary to the myocyte, thus rendering the myocardium oxygen deprived and
more susceptible to ischaemic damage. This concept has been supported by
experimental studies, showing a larger infarct size following ischaemia in the
subtotally nephrectomised rat heart (Dikow et al., 2004). Moreover, a decreased
oxygen supply to the cardiomyocyte may compromise mitochondrial function,
resulting in a loss of mitochondrial membrane potential and consequently reduced
ATP synthesis, which may contribute to the inability of the uraemic heart to adapt
to haemodynamic alterations (Seymour, 2003a). Additionally, loss of mitochondrial
integrity initiates the apoptotic cascade (Borutaite and Brown, 2003), ultimately
leading towards the deterioration of ventricular function and, in turn, progression
to heart failure (Figure 1.5).
Figure 1.5: Diagram showing the sequence of14 | P a g e
events leading to heart failure in uraemia
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1.5 Cardiac Fibrosis
A further detrimental characteristic of CKD is myocardial fibrosis. During LVH,
coupled with the enlargement of cardiomyocytes is the expansion of extracellular
matrix (ECM) to preserve myocardial structural integrity. When the heart is
subjected to a chronic increase in demand (such as prolonged pressure or volume
overload), collagen, the principle component of ECM, accumulates
disproportionally, leading to cardiac dysfunction (Weber, 1989).
1.5.1 Extracellular Matrix (ECM)
The ECM can be organised into three distinct forms. The endomysium, which
surrounds individual cardiomyocytes, the perimysium, which envelopes bundles of
myocytes, and the epimysium, which is the ECM surrounding the whole heart
(Weber, 1989, Weber et al., 1994) (Figure 1.6).
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ECM is comprised primarily of collagen, with lesser amounts of fibronectin, laminin
and elastin. Over 20 types of collagen fibres exist, which vary depending on their
polypeptide chain sequence. The primary collagen fibres within the normal heart
are type I, III and V accounting for 85%, 11% and 3% of the total collagen
respectively (Weber et al., 1988).
Type I collagen fibres consist of two α1 polypeptide chains and one α2 chain, with
repeating glycine units, which are tightly wound to form a triple helical structure
(van der Rest and Garrone, 1991). Collagen synthesis takes places within cardiac
Figure 1.6: Diagram of ECM distribution in muscle
(Adapted from(Hunter and Harris, 2008)
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fibroblasts, which are also responsible for the production of other ECM components
including glycosaminoglycans and glycoproteins. Pro-α chains are synthesised on
ribosomes of the rough endoplasmic reticulum (ER). They are then secreted into the
ER lumen where they combine with 2 other pro-α chains to form a hydrogen-
bonded helix, known as procollagen (Ricard-Blum and Ruggiero, 2005). Procollagen
contains extra amino acids, or propeptides, at the C- and N- terminals, which are
cleaved once the procollagen has been secreted into the extracellular space,
forming tropocollagen. Tropocollagens aggregate to form collagen fibrils, which can
then be assembled into larger collagen fibres, which are visible under a light
microscope (Church et al., 1971).
Experimental models (Amann and Ritz, 1996, Kalk et al., 2007, Mall et al., 1988) and
post-mortem studies (Mall et al., 1990) have both revealed extensive interstitial
fibrosis in the uraemic heart. Experimental studies using the 5/6th nephrectomy
model have shown that uraemia enhances the activation and proliferation of
cardiac interstitial fibroblasts (Mall et al., 1988, Amann and Ritz, 1997, Amann et al.,
1994). Interestingly, the fibrosis observed in hearts from uraemic patients was
significantly more pronounced than in non-renal hypertensive controls (Mall et al.,
1990). Furthermore, Amann et al (1998b) showed that myocardial fibrosis, during
experimental CKD, occurs independent of hypertension and LVH.
The presence of myocardial fibrosis contributes toward the development of heart
failure and has functional consequences, including arrhythmias and reduced
ventricular compliance, leading to impaired relaxation and diastolic dysfunction
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(Saito et al., 2007, Varnava et al., 2001). Importantly, diastolic dysfunction is
frequently observed in patients with CKD (Otsuka et al., 2009). The deposition of
collagen fibres between capillaries and myocytes may also contribute to oxygen
depletion (Figure 1.5). Indeed, a mismatch between oxygen supply and demand
decreases the tolerance of the uraemic heart to ischaemic insults (Dikow et al.,
2004). In support of this, clinical studies have demonstrated that patients with renal
insufficiency have an increased risk of death following acute myocardial infarction
(Shlipak et al., 2002).
1.6 Erythropoietin (EPO)
Hypoerythropoietinaemia is an established consequence of uraemia (Caro et al.,
1979, Eschbach et al., 2002). In addition to decreased EPO production, EPO
resistance may also occur in CKD patients due to the production of inflammatory
cytokines, including IL-6 and TNFα (Goicoechea et al., 1998). Since the cloning of
the gene in 1985, EPO has been widely used as a treatment for anaemia and its use
has revolutionised the treatment of CKD (Lin et al., 1985). The haemopoietic effects
of EPO are well known, although the effects of EPO extend well beyond the bone
marrow.
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1.6.1 Biochemistry of EPO and EPO Receptor
EPO is a 165 amino acid glycoprotein hormone (30.4kDa) belonging to the type 1
cytokine family (Maiese et al., 2005). Its primary role is to regulate erythropoiesis
(production of red blood cells) by controlling the proliferation, differentiation and
survival of erythrocytes (Fisher, 2003). During development, the source of EPO
production switches from the foetal liver to the peritubular fibroblast cells in the
inner cortex and outer medulla of the adult kidney (Lacombe et al., 1988). When
the cellular demand for oxygen exceeds supply, cells express hypoxia inducible
factor 1 (HIF1), which controls oxygen homeostasis (Wang et al. 1995). HIF-1
comprises two subunits, HIF1α and HIF1β. Under normoxic conditions, HIF1α
undergoes prolyl hydroxylation, which provides a binding site for E3 ubiquitin ligase
containing von Hippel-Lindau tumour-suppressor protein (VHL), resulting in
proteasomal degradation. During hypoxia, HIF prolyl-hydroxylation is inhibited
leading to HIF-1 activation and increased transcription of a number of proteins,
including EPO and vascular endothelial growth factor (VEGF) (Semenza, 1994).
The effects of EPO are mediated through its specific cellular receptor EPOR. EPOR is
a type I transmembrane receptor belonging to the cytokine receptor superfamily
(Smith et al., 2003). Upon binding, EPO causes homodimerisation of EPOR, causing
the phosphorylation and subsequent activation of the receptor-associated Janus
Kinase2 (Jak2) (Witthuhn et al., 1993). This results in the phosphorylation of
tyrosine residues in EPOR and successive activation of signalling molecules with Src
homology domains, including signal transducer and activator of transcription 5
(STAT5) and phosphatidylinositol 3-kinase (PI3K) (Figure 1.7) (Sawyer and Penta,
1996, Um and Lodish, 2006).
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C; Stat5 signal transducer and activator of transcription 5.
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Activation of Stat5 promotes transcription of anti-apoptotic genes, including Bcl-X
(Silva et al., 1999, Socolovsky et al., 1999). Indeed, STAT5a-/- and STAT5b-/- mice
show severe anaemia and increased apoptosis, thus suggesting a direct role for
STAT5 in the development and survival of erythrocytes (Socolovsky et al., 1999).
Stimulation of the PI3K pathway and downstream activation of Akt also reduces
erythroblast apoptosis through modulation of pro- and anti-apoptotic proteins
including Bad and caspase 9 (Hanlon et al., 2005, Parsa et al., 2003, Smith et al.,
2003, Wojchowski et al., 1999).
1.6.2 Cardiovascular effects of EPO
The recent discovery that EPOR is also expressed on non-haematopoietic tissue
including neurons (Digicaylioglu and Lipton, 2001, Brines et al., 2000) retinal cells
(Junk et al., 2002), smooth muscle cells (Ammarguellat et al., 1996), endothelial
cells (Anagnostou et al., 1994) and cardiomyocytes (Brines et al., 2004, Depping et
al., 2005, van der Meer et al., 2004, Wright et al., 2004) highlights a role of EPO
beyond erythropoiesis.
The protective effect of EPO was first demonstrated in ischaemic brain injury.
Bernaudin et al. (2000) showed a rapid increase in EPOR expression in the presence
of ischaemia, correlating with a decrease in caspase-3 cleavage and apoptotic cell
death (Bernaudin et al., 2000). In a rat stroke model, EPO reduced the area of
neural damage, even when administered 6 h after cerebral artery occlusion (Brines
et al., 2000). Furthermore, clinical studies have shown that EPO is safe and well
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tolerated, when administered after an acute ischaemic stroke and is associated
with a reduction in infarct size (Ehrenreich et al., 2002).
The role of EPO as a cardioprotectant has since been reiterated (Moon et al., 2003a,
Shi et al., 2004, Wright et al., 2004). There is little experimental data on the direct
effects of EPO in the uraemic heart, however, parallels can be drawn based on
animal models of heart failure.
The mechanisms underlying the cardioprotective effect of EPO have not yet been
fully elucidated. Improved cardiac function may be partly explained via the up-
regulation of erythropoiesis. Indeed, stimulating red blood cell production increases
the delivery of oxygen to the myocardium and improves function (Fisher, 2003).
However, EPO can exert beneficial effects on ex-vivo hearts (Wright et al., 2004)
and isolated cardiomyocytes (Calvillo et al., 2003). Furthermore, chronic
administration of low-dose EPO improved function in an experimental model of
post-MI heart failure, without modifying haematocrit (Ben-Dor et al., 2007, Lipsic et
al., 2008). Carbamylated erythropoietin (CEPO) is an analogue of EPO that does not
bind to the dimeric EPOR and therefore lacks the ability to stimulate erythropoiesis.
Administration of CEPO resulted in improved left ventricular function, in addition to
a 50% reduction in apoptosis, in an experimental model of post-MI heart failure
(Fiordaliso et al., 2005, Moon et al., 2006). These data therefore indicate that the
cardioprotective effects of EPO are independent from its haematopoietic effects.
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1.6.2.1 Acute Cardioprotective Effects
The prevention of cardiomyocyte apoptosis is pivotal in the acute cardioprotective
effects of EPO. During LVH, the myocardium has a limited adaptive response to the
activation of stress pathways, which predisposes some cells to damage and loss
through apoptosis (programmed cell death) (Foo et al., 2005). The gradual loss of
irreplaceable cardiomyocytes via apoptosis can impair function and may play a
central role in the gradual progression to heart failure (Anversa et al., 1996, Gupta
et al., 2007, Sharma et al., 2007). Indeed, both experimental (Cheng et al., 1996)
and clinical studies (Olivetti et al., 1997) show myocyte apoptosis to be a major
characteristic of the failing heart. Apoptosis is an energy requiring, tightly
controlled process, characterised by nuclear condensation, membrane blebbing and
cell shrinkage (Kunapuli et al., 2006). In response to a variety of stimuli, including
mechanical stretch and hypoxia, apoptosis can be triggered via two main routes,
the extrinsic and intrinsic (mitochondrial) pathway (Figure 1.8).
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Pro-apoptotic compounds (such as Bax) and damage to mitochondria via oxidative
stress (including reactive oxygen species; ROS) or other agents, can trigger the
release of cytochrome c, which stimulates apoptosis via activation of caspase 9, and
subsequent activation of caspase 3 (Borutaite and Brown, 2003) (Figure 1.8).
Cytochrome c release occurs from the opening of the mitochondrial permeability
transition pore (MPTP) (Zoratti and Szabo, 1995). In response to stress, the inner
mitochondrial membrane becomes permeabilised by the opening of MPTP,
resulting in loss of ion homeostasis (Halestrap, 2009). The free movement of ions
causes mitochondria to swell, resulting in rupture of the outer membrane, thereby
releasing cytochrome c from the inter membrane space. Interestingly, several
experimental studies have shown that inhibiting MPTP opening improves function
and protects the heart during ischaemia/ reperfusion (Nazareth et al., 1991, Xu et
al., 2001).
A number of experimental studies have shown that EPO reduces apoptosis in
cultured neonatal myocytes (Calvillo et al., 2003, Tramontano et al., 2003).
Moreover, administration of EPO reduced ventricular dysfunction, improved
ejection fraction and ameliorated apoptosis after induction of MI in rats (Bullard
and Yellon, 2005).
The mechanisms underlying EPO-mediated cardioprotection remain incompletely
understood. Associated with EPO-EPOR interaction is the reperfusion injury salvage
kinase (RISK) pathway, involving activation of extracellular signal-related kinase-1
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(ERK-1) and PI3K/Akt, which are central to anti-apoptotic signalling (Tramontano et
al., 2003, Cai and Semenza, 2004). The role of the PI3K/Akt pathway in the
cardioprotective effect of erythropoietin has been substantiated using specific
inhibitors of PI3K. Several studies report that the protective effects (improved
cardiac function and reduced apoptosis), following EPO treatment, are diminished
in the presence of the PI3K inhibitors, LY294002 and wortmannin (Parsa et al.,
2003, Sivertsen et al., 2006). More recently it has been shown that the EPO-
mediated reduction in cardiomyocyte apoptosis is via downstream effects of Akt
activation, through deactivation of glycogen synthase kinase (GSK)-3β and, via
protein kinase G (PKG) phosphorylation, protein kinase C (PKC) activation (Ohori et
al., 2008). Both of these effects, either directly or indirectly, inhibit the opening of
MPTP (Figure 1.7) (Ohori et al., 2008, Kim et al., 2006). Further support for this
comes from findings combining treatment with EPO and the PKC inhibitor,
chelerythrine, which reduced functional recovery of hearts when compared with
EPO treatment alone (Rafiee et al., 2005). Shi et al. (2004) showed that the
improved functional recovery observed in EPO treated hearts was also abolished in
the presence of the mitochondrial ATP-sensitive potassium (mKATP) channel blocker,
glibenclamide (Shi et al., 2004) (Figure 1.7).
Although the prevention of myocyte apoptosis is central to the cardioprotective
actions of EPO, several studies report other cellular effects. EPO treatment caused
a reduction in oxidative stress and a decreased production of the pro-inflammatory
cytokines, IL-1β, IL-6 and TNFα, in an animal model of post-MI heart failure (Li et al.,
2006). Furthermore, studies show that EPO is involved in the mobilisation of
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endothelial progenitor cells (EPC’s), thus promoting vascular repair (Urao et al.,
2006, d'Uscio et al., 2007).
EPO has also been shown to modulate nitric oxide (NO) production, via up-
regulation of eNOS. The anti-apoptotic effects of NO are well documented and
include inhibition of NADPH oxidase, thus limiting oxidative stress and cellular
damage (Razavi et al., 2005, Smith et al., 2005). Indeed, the protective effect of EPO
was abolished in eNOS-deficient mice (Burger et al., 2006). Furthermore, several
studies have demonstrated that the anti-apoptotic effect of EPO was abrogated in
cultured myocytes, when incubated in the presence of the NOS inhibitor, L-NAME
(Bullard and Yellon, 2005, Burger et al., 2006, Joyeux-Faure et al., 2006). EPO is
thought to increase eNOS expression via activation of the PI3K/Akt pathway (Rui et
al., 2005). In contrast, Shi et al. (2004) found that L-NAME did not abolish the
cardioprotective effect of EPO during ischaemia-reperfusion in isolated rabbit
hearts (Shi et al., 2004).
1.6.2.2 Chronic Cardioprotective Effects
Chronic EPO treatment has beneficial effects, however, the mechanisms underlying
these have not yet been fully elucidated. Experimental models of ischaemic heart
disease and heart failure have shown that chronic EPO administration stimulates
angiogenesis and vascular sprouting (Nishiya et al., 2006, van der Meer et al., 2005,
Westenbrink et al., 2007). Interestingly, Jaquet et al (2002) demonstrated that EPO
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stimulated angiogenesis (in vitro) to the same degree as VEGF in myocardial tissue
(Jaquet et al., 2002). Furthermore, the administration of EPO to heart failure
patients resulted in increased endothelial progenitor cell (EPC) proliferation
(George et al., 2005). Westernbrink et al. (2007) showed that EPO induced EPC
mobilisation and incorporation of these bone-marrow derived EPCs into the
endothelium of newly formed vessels.
Chronic EPO administration can ameliorate cardiac fibrosis, potentially, via
inhibition of transforming growth factor (TGF)β (Shushakova et al., 2009). In the
post-MI rat heart, Nishiya et al. (2006) observed a reduction in cardiac fibrosis in
non-infarcted regions, when EPO was given once a day for 4 days (5000U/Kg) and
when administered 3 times a week for 4 weeks (1000U/Kg) post-surgery. As
previously mentioned, EPO modulates NO activity, which, in addition to its anti-
apoptotic actions, also plays a key role in cell growth, contractile function and
vascular homeostasis (Seddon et al., 2007). Non-specific inhibition of NOS has been
shown to increase fibrosis following MI (Silvestre et al., 1999). Whereas adenoviral
gene transfer of eNOS, in a rat model of post-MI heart failure, caused a decrease in
myocardial fibrosis and reduced oxidative stress (Smith et al., 2005). These studies
highlight the beneficial effects of EPO-mediated up-regulation of NO.
Clinical studies investigating the cardiovascular effects of EPO in CKD have provided
somewhat conflicting results. Some studies have shown that administering EPO to
partially or fully correct the anaemia associated with CKD induces a regression of
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LVH (Silberberg et al., 1990, Hayashi et al., 2000). A reduction in LV mass has been
associated with improved survival and reduced hospitalisations in uraemic patients
(London et al., 2001).
The CREATE trial demonstrated an improvement in general health and physical
capacity in CKD patients with a haemoglobin corrected to within the normal range
(13-15g/dL) compared with patients with a subnormal haemoglobin (10.5-
11.5g/dL). Interestingly however, no differences were observed in the incidence of
cardiovascular events between the two groups (Drueke et al., 2006). A second large
clinical trial, the CHOIR trial showed that correcting anaemia to a target
haemoglobin of 13.5g/dL did not result in an improved quality of life and actually
increased the risk of cardiovascular events in CKD patients (Singh et al., 2006).
Further large-scale clinical trials are required to elucidate the potential beneficial
effects of EPO.
1.7 Objectives
Uraemic cardiomyopathy is associated with anaemia, hypertension and LVH which
contribute to heart failure. EPO is widely used in CKD patients to improve
haematocrit. Interestingly, recent studies have observed cardioprotective effects of
EPO, independent from erythropoiesis. However, little is known regarding the
direct impact of EPO on the uraemic heart. Therefore, this study aims to examine
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the functional, structural and metabolic changes in uraemic cardiomyopathy and
the effects of chronic EPO administration. Specifically, the aims of this study were
 To determine the impact of uraemia on cardiac function in vitro and in vivo
 To analyse the effect of acute and chronic EPO treatment on cardiac
function
 To assess the extent of cardiac metabolic remodelling in uraemia, and the
impact of chronic EPO administration
 To identify the extent of myocardial fibrosis in uraemia and the impact of
chronic EPO treatment
 To determine the effect of uraemia and chronic EPO administration on in
vitro myocardial mitochondrial function
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Chapter 2: Materials and Methods
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2.1 Materials
Table 2.1 provides a list of the materials used in this study. Chemicals were all of
analaR grade and purchased from BDH (Poole, UK) unless otherwise stated.
Surgical materials were purchased from NHS supplies (IVF unit, Hull Royal Infirmary,
UK).
Table 2.1: Materials and Suppliers
Suppliers Materials
Abbott Laboratories,
Kent, UK
Isoflurane
Amgen Ltd.
Cambridge, UK
Aranesp® (Darbepoetin alfa)
Apollo Scientific Ltd.
Stockport, UK
Deuterated water (D2O)
Biorad Laboratories,
Munich, Germany
Bio-rad Protein Assay
British Oxygen Corporation,
Manchester, UK
Oxygen
Cambridge Isotope Laboratory,
Andover, USA
[U-13C] Sodium Palmitate
[1-13C] D-Glucose
Proliant Health & Biologicals
Iowa, USA
Bovine serum albumin (fatty acid free
<0.001%)
Fisher Scientific,
Leicester, UK
L-glutamine
(BP379-100)
Harvard Apparatus,
Edenbridge, UK
Gaseous anaesthetic (Fluovac vacuum
pump, Veterinary fluosorber and
Ohmeda Fluotec vaporizer)
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Intervet UK Ltd.
Cambridge, UK
Amphipen
Johnson & Johnson,
North Yorks, UK
Ethicon 3-0 (Vicryl braided)
Ethicon 3-0 (Blue monofilament)
Mersilk 3-5 (Silk braided)
Surgicel®
Merial Animal Health,
Harlow, UK
Halothane
Millipore,
Ireland
0.45μm filter (HA type)
5.0μm filter (SVPP type)
Nestle,
UK
Marvel milk powder
Novartis Animal Health,
Herts, UK
Thiovet (sodium thiopentone)
Pall Life Sciences,
USA
Acrodisc® (0.2μm syringe filter)
Pfizer Ltd.
Sandwich, UK
Rimadyl (5% w/v Carprofen)
Roche Diagnostics,
Penzberg, Germany
Complete® Protease inhibitor cocktail
Sakura Finetek
Zoeterwoude, Netherlands
Tissue-Tek OCT compound
Sigma-Aldrich Company
Poole, UK
2,2’-Azino-bis (3-Ethylbenz-Thiazoline-
6-Sulphonic Acid) - ABTS
Acetyl CoA
Amyloglucosidase
Bovine serum albumin (BSA)
Bromophenol blue
CoA
Chelex-100 sodium form
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Sigma-Aldrich Company
Poole, UK (continued)
Dichloroacetic acid
Direct Red 80
EGTA
Fast Blue RR Salt
Glucose oxidase
Glycerol
HEPES
Imidazole
Insulin
Lactate dehydrogenase
Lactate (sodium salt)
Leupeptin
Malate
2- Mercaptoethanol
Octanyl Co-A
Palmitic acid (sodium salt)
Palmitoyl carnitine
Percoll
Peroxidase
Pyruvate (sodium salt)
Sodium Tetrathionate
sodium dodecyl sulphate (SDS)
Sucrose
TRIS
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2.2 Methods
All animal procedures conformed to the UK Home Office guidelines on the
operation of laboratory animals (Scientific Procedures Act 1986).
2.2.1 Induction of Uraemia
Uraemia was induced surgically in male Sprague-Dawley rats (weighing
approximately 250g) via a one-stage 5/6th nephrectomy (modified from(Reddy et
al., 2007, Raine et al., 1993). Briefly, animals were anaesthetised with 3.5%
isoflurane in 3L/min oxygen and Rimadyl administered (4 mg/Kg body weight), by
subcutaneous injection, for post-operative pain relief. Throughout the surgical
procedure, anaesthesia was maintained using 2.5% isoflurane in 1 L/min oxygen.
Depth of anaesthesia was indicated using the pedal withdrawal reflex.
A midline abdominal incision was made and the left kidney exposed and
decapsulated. Approximately two-thirds of the kidney was removed. Surgicel®
(Johnson & Johnson, UK) was used to stem excessive bleeding and the remnant
kidney replaced. Subsequently, the right kidney was located and decapsulated. The
renal vessels were ligated using a non-absorbable suture (Mersilk® Johnson &
Johnson, UK) and the whole kidney removed. Abdominal musculature was closed
using an absorbable suture (Ethicon 3-0 Vicryl braided, Johnson & Johnson, UK).
Non-absorbable sutures (Ethicon 3-0 blue monofilament, Johnson & Johnson, UK)
were used to close the skin layer.
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In control animals, a sham procedure was performed whereby kidneys were solely
decapsulated and replaced intact. The incision was closed as described above. To
compensate for fluid loss during surgery, sterile isotonic saline (0.9% w/v) was
administered into the abdominal cavity prior to closure of the layer.
Rats were maintained for 3, 6, 9 or 12 weeks post-surgery. Animals were housed
individually with 12:12hr light:dark cycles. Uraemic animals were pair-fed with
sham operated animals, a diet of standard rat chow. Water was available ad libitum
for both animal groups.
2.2.2 Preparation of Krebs-Hensleit (K-H) Buffer
Hearts were perfused in vitro using Krebs-Henseleit (K-H) buffer containing 3%
bovine serum albumin (BSA) and the following components (mM); NaCl (118.5),
NaHCO3 (25), KCl (4.8), KH2PO4 (1.2), MgSO4 (1.2), CaCl2 (1.25), glucose (5)
(unlabelled or 100% 1-13C labelled), sodium pyruvate (0.1), sodium lactate (1),
sodium palmitate (0.3) (unlabelled or 50% U-13C labelled), glutamine (0.5) and 0.1
mU/L insulin. Buffers were freshly prepared using ultra pure water (18MΩ) gassed
with 95% O2 5% CO2 and filtered using a 0.45 μm Millipore filter.
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2.2.3 Preparation of Bovine Serum Albumin (BSA)
300 g BSA, essentially fatty acid free (< 0.001%), was dissolved in 1 L ultra pure
water (18 MΩ) containing 118 mM NaCl and 2.5 mM CaCl2. Lengths of dialysis
tubing were boiled for 10 minutes in 1 mM EDTA containing 2% (w/v) NaHCO3. The
tubing was then rinsed in ultra pure water, boiled for a further 10 minutes in 1 mM
EDTA and rinsed again using ultra pure water. The tubing was cooled and stored at
4˚C.
The BSA solution was poured into prepared tubing and dialysed against 20L ultra
pure water (18MΩ) containing 118 mM NaCl and 2.5 mM CaCl2 at 4°C. After 48 h
the BSA was separated into 10 equal aliquots (30% concentration) and stored
at –20˚C until required.
A correction was made to allow for NaCl and CaCl2 already present in the BSA
solution (Equation 1). This value was then deducted from the amount of NaCl and
CaCl2 required in the K-H buffer.
ܯ ܽݏݏ݋݂ ݋ܿ݉ ݌݋ݑ݊݀ ݅݊ ܤ ܵܣ (݌݁ ݎ݈݅ݐ݁ݎ )= ܸ݋݈ ݑ݉݁݋݂ ܤ ܵܣ (ܮ) × ܯ ݋݈ ݁ܿ ݑ݈ܽ ݎܹ ݁݅݃ℎݐ× ܯ ݋݈ ܽ݅ݎݐݕ (ܯ )
Equation 1: Calculation for NaCl and CaCl2 present in BSA solution
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For example, when using BSA with an aliquoted volume of 170 ml, the amount of
NaCl present in the BSA = 0.170 × 58.44 × 0.118 = 1.17g (per litre). This value can
then be deducted from the amount required in the K-H buffer, for example when
making up a litre of buffer (which requires 6.89g NaCl) the calculation would be
6.89 - 1.17 = 5.72g.
For the addition of palmitate, sodium palmitate (unlabelled or 50% U-13C labelled)
was dissolved in boiling ultra pure water (18MΩ) and added slowly to the BSA
solution. Subsequently, this mixture was added to the filtered K-H buffer and
filtered again using a 5.0μm Millipore filter.
2.2.4 Heart Perfusion
Animals were anaesthetised with an i/p injection of sodium thiopentone (100mg/Kg
body weight). Hearts were excised and immediately placed in ice-cold K-H buffer.
Hearts were cannulated via the aorta and perfused in a modified isovolumic
Langendorff mode (Sample et al., 2006) using BSA K-H buffer gassed with 95% O2
5% CO2 and maintained at 37°C throughout (Figure 2.1).
The apex of the left ventricle was pierced using a 21G needle, passed
mitral valve, to prevent accumulation of fluid. A balloon made o
connected to a physiological pressure transducer (SensNor, Horten, N
fluid filled line, was inserted into the left ventricle, via the mitral valve
contractile function continuously (Figures 2.1 and 2.2). The balloon
adjusted using a micrometer syringe (Gilmont Instruments, Barrington
left ventricular diastolic pressure (DP) of approximately 5-7 mmHg w
(Pabla and Curtis, 1996)
Figure 2.1: Isovolumic Langendorff perfusion apparatus
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2.2.4.1 Pacing
Prior to the insertion of the balloon, the atrioventricular (AV) node was crushed and
copper wires were inserted into the heart using 25G needles (Figure 2.2). Wires
were connected to the PowerLab stimulator output, which delivered a 1 msec
pacing pulse. The pacing voltage was set between 400 mV- 1500 mV and hearts
were paced at 300 bpm.
Figure 2.2: Isolated perfused rat heart
Pacing wire
Cannula
Clingfilm
balloon
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2.2.4.2 In Vitro Cardiac Function
Cardiac function was recorded via a bridge amplifier and PowerLab (4/30) using the
software, Chart 5.5, and the additional ‘blood pressure module’ (ADInstruments,
Hastings, UK). Heart rate (HR), systolic (SP) and diastolic pressures (DP) were
continuously recorded throughout the perfusion. Left ventricular developed
pressure (LVDP) was calculated by subtracting diastolic from systolic pressure
(Figure 2.3) and rate pressure product (RPP), a measure of cardiac work, was
calculated using Equation 2.
ܴܲܲ = ܪܴ × ܸܮ ܦܲ
Equation 2: Calculation for determining RPP
LVDP
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DP
Figure 2.3a: Recording of cardiac function
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To determine the rate of cardiac contractility, dP/dtmax and dP/dtmin were derived
and recorded throughout the perfusion (Figure 2.4).
2.2.4.3 Oxygen Consumption (MVO2)
To calculate the MVO2 of perfused hearts, perfusate and effluent samples were
taken at 15 minute intervals throughout the perfusion. The pO2 content was
measured using an ABL77 blood gas analyser (Radiometer Ltd. West Sussex, UK).
Oxygen consumption (μmoles/g wet weight/min) was calculated using Equation 3
(Neely et al., 1967).
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Figure 2.4: Recording of cardiac contractility
dP/dtmax
dP/dtmin
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cardiac failure, lungs were weighed and dried to determine the
ater (Equation 4). At the end of the perfusion protocol, atria were
tricular tissue freeze clamped using Wollenberger tongs immersed
. Heart tissue was stored at -80°C until required.
quation 4: Calculation for determining % lung water
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2.2.4.4 Indices of Hypertrophy
At the time of sacrifice, body weight (BW), wet heart weight (HW) and tibia length
were recorded. HW: BW and HW: tibia length were calculated to determine the
degree of cardiac hypertrophy in uraemic animals (Yin et al., 1982).
2.2.4.5 Haematocrit and Serum Analysis
Immediately after excision of the heart, 1 ml of blood was taken from the chest
cavity into a heparinised syringe for determination of haematocrit using a blood gas
analyser (ABL77 Radiometer, UK). The remaining blood was taken from the chest
cavity and centrifuged at 4000 g for 10 minutes at 4°C. Serum was removed and
stored at -20°C. Serum urea and creatinine were analysed at Clinical Biochemistry,
Hull Royal Infirmary, Hull and East Yorkshire NHS trust.
2.2.5 13C NMR Spectroscopy
2.2.5.1 Perchloric Acid (PCA) Tissue Extraction
Frozen ventricles were ground to a fine power under liquid nitrogen using a mortar
and pestle. Approximately 1 g powered ventricular tissue was added to 6% PCA at a
ratio of 1:5 (w/v) (Seymour et al., 1990). The suspension was left on ice for 10
minutes. Samples were centrifuged at 3000g for 10 minutes at 4˚C and the
supernatant adjusted to pH 6.5 using 6 M KOH. Samples were centrifuged and the
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neutralised supernatant removed, frozen in liquid nitrogen and lyophilised for 48 h
in a freeze dryer (Modulyo, BOC Edwards, UK).
2.2.5.2 Preparation of NMR samples
A phosphate buffer containing 50 mM KH2PO4 (pH 6.5) was prepared and
lyophilised for 48 h using a freeze dryer. The buffer was reconstituted using
deuterium oxide (D2O).
The lyophilised tissue extract was reconstituted with 0.95 ml deuterated phosphate
buffer. A small spatula of a chelating resin (chelex 100-sodium form, Sigma, Poole,
UK) was added to remove paramagnetic ions. Following this, the sample was
filtered into a 5 mm NMR tube through a 0.2 μm syringe filter (Acrodisc® Pall Life
Sciences, USA).
2.2.5.3 Acquisition of 13C Spectra
High-resolution 1H decoupled (WALTZ 16 decoupling) 13C NMR spectra were
collected at 500 MHz using an 11.7 Tesla ultra-shielded superconducting vertical
wide bore Bruker magnet (Bruker, Coventry, UK) and 5 mm broadband probe,
interfaced with a Bruker spectrometer. Free induction decays (FIDs) were acquired
over 36000 scans with a 90° pulse (9.95 µs pulse duration and 1 s interpulse delay)
and fourier transformed spectra were analysed using Bruker Topspin (1.3) software.
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2.2.5.4 13C Labelling Profiles
One-13C labelled glucose and U-13C labelled palmitate generate [2-13C] and [1, 2-13C]
labelled acetyl-CoA, respectively. When acetyl-CoA enters the TCA cycle, the 13C
labels appear within TCA cycle intermediates, however these intermediates are in
insufficient quantities to be detected by NMR analysis. However, α-ketoglutarate is
in rapid exchange with glutamate, which is present in sufficient quantities to detect
the 13C label (Chance et al., 1983).
When [2-13C] labelled acetyl-CoA (from 1-13C glucose) enters the TCA cycle and
combines with oxaloacetate, the label appears on the C4 of α-ketoglutarate and
subsequently the C4 of glutamate. As the labelled α-ketoglutarate is further
metabolised in the TCA cycle, the label is scrambled randomly to either the C2 or C3
position of fumarate, and thus the C2 or C3 in oxaloacetate. On the next turn of the
TCA cycle, the oxaloacetate (labelled in either the C2 or C3 position from the
previous round) then combines with another 2-13C labelled acetyl-CoA, giving rise to
glutamate labelled in either the C3 and C4 or C2 and C4 position. With successive
turns of the TCA cycle, the label is transferred to the C2, C3 and C4 positions of
glutamate (Figure 2.5a).
[U-13C] labelled palmitate produces [1, 2 13C] labelled acetyl-CoA which enters the
TCA cycle, producing glutamate labelled in the C4 and C5 position. As described
above, scrambling of the label occurs as α-ketoglutarate continues through the TCA
cycle producing oxaloacetate labelled in either C4 and C3, or C2 and C1 position.
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With successive turns of the TCA cycle, the label appears in C5, C4 and C3 or C5, C4,
C2 and C1 of glutamate (Figure 2.5b).
When hearts are perfused with both 1-13C glucose and U-13C palmitate, 9 peaks are
observed in the C2 and C4 region and 5 peaks are seen in the C3 region of the
glutamate spectra (Figure 2.6).
Figure 2.5a: Profile following 1-13C glucose49 | P a g e
(adapted from Seymour 2003)
Figure 2.5b: Profile following U-13C palmitate50 | P a g e
(adapted from Seymour 2003)
C2
C4 C3Figure 2.6: 13C NMR spectra showing expansion of51 | P a g e
resonances of glutamate
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The isotopomers of glutamate were analysed using the TCAcalc program, kindly
provided by Dr Mark Jeffrey (University of Texas, USA). The peak intensities of C2,
C3 and C4 resonances of glutamate and the ratio of the integrated areas under C3
and C4 resonances (Figure 2.6) were determined, and the contribution of
exogenous 13C-labelled substrates to acetyl-CoA entering the TCA cycle and thus the
relative contributions of exogenous 13C labelled substrates to oxidative metabolism
calculated.
The relative fractional enrichments of acetyl-CoA can be defined as follows.
 Fc0 is the fraction of acetyl-CoA which is generated from unlabelled
substrates.
 Fc1 is the fraction of acetyl-CoA with the
13C label appearing on the first
(carbonyl) carbon.
 Fc2 is the fraction with the
13C label appearing on the methyl carbon (2nd
carbon) of acetyl-CoA (e.g. when using 1-13C glucose)
 Fc3 is the fraction of acetyl-CoA that has a
13C label in both C1 and C2 of
acetyl-CoA (e.g. when using U13-C palmitate).
By definition Fc0 + Fc1 + Fc2 + Fc3 = 1.
TCAcalc is based on the following assumptions (Malloy et al., 1988, Malloy et al.,
1990)
 All carbon enters the TCA cycle via acetyl-CoA or through anaplerosis (that is
carbon entering the TCA cycle from sources other than acetyl-CoA), which is
assumed to be 0.1.
 The TCA cycle is in a steady state
 α-ketoglutarate and glutamate are in constant rapid exchange
 Scrambling of the label occurs randomly at fumarate
 The natural abundance of 13C does not influence the labelling pattern
Every glucose molecule produces two molecules of acetyl-CoA and therefore the
relative contribution obtained must be multiplied by two. Similarly, the relative
contribution obtained for palmitate must also be multiplied by two because only
50% [U-13C] labelled palmitate was used for perfusions
2.2.6 Biochemical Assays
2.2.6.1 Pyruvate Dehydrogenase (PDH) Assay
PDH was assayed using the method of(Seymour and Chatham, 199
the active fraction of PDH (PDHa), the in situ state of the enzyme
by inclusion of specific inhibitors of PDH phosphatase (KH2PO4 a
kinase (ADP and DCA). To extract total PDH (PDHt), the enzyme wa
the active form by stimulating PDH phosphatase and inhibiting PDH
Approximately 200 mg ground ventricular tissue was extracted in
homogenisation buffer (1:5 w/v) (Table 2.2) and homogenised at
using an Ultra Turrax T25 homogeniser (IKA® Labortechnik, Germa53 | P a g e
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sample was rapidly frozen in liquid nitrogen, thawed and homogenised for a further
30 s. The freeze-thaw cycle was repeated, totalling 3  30 s homogenisations.
Subsequently, samples were centrifuged at 13,000 g for 7 min at 4C, and the
supernatant assayed.
Table 2.2: Components of PDHt and PDHa homogenisation buffers
Active PDH homogenisation
buffer (pH 7)
Total PDH homogenisation
buffer (pH 7)
25 mM HEPES 75 mM HEPES
25 mM KH2PO4 5 mM DCA
25 mM KF 5 mM MgCl2
1 mM DCA 1 mM ADP
3 mM EDTA 1 mM DTT
1 mM ADP 0.05 mM Leupeptin
1 mM DTT 1% (v/v) Triton-X
0.05 mM Leupeptin
1% (v/v) Triton-X
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PDH activity was assayed spectrophotometrically by monitoring the rate of NADH
formation. The reaction buffer contained (in mM unless otherwise stated) 50
HEPES, 1 MgCl2, 0.08 EDTA, 1 DTT and 4M Rotenone (pH7.2).
The reaction buffer (0.75 ml), along with 50 l of the following (mM) 1.67 NAD, 0.1
CoA, 0.2 TPP, and 16.7 lactate, were added to a cuvette. Five micro-litres LDH (to
give a final concentration of 2 U) was added and the mixture incubated at 30C for
5 minutes. Twenty micro-litres of total extract or 100 l of the active extract were
added and the change in absorbance determined at 340 nm over 3 min. PDH
activity was calculated using Equation 5 and an extinction coefficient of 6.22 mM-
1cm-1.
To ensure there were no variations in the extraction procedure, citrate synthase
activity was determined in total and active extracts using the reaction buffer as
described in Section 2.2.6.2.
൬
ܣ ܾݏ ℎܿܽ݊݃ /݁݉ ݅݊
ܧݔ݅ݐ݊ ܿ݅ݐ݋݊ ܥ݋݁ ݂݂ ݅ܿ ݅݁ ݊ݐ
൰ × ቆܶ݋ܽݐ ݈ ܿݑ݁ݒ ݐ݁ݐ ݒ݋݈ ݑ݉݁(݉ )݈
ܸ݋݈ ݋݂ ݏݑ݌ ݁݊ݎ ܽܽݐ ݊ݐ
ቇ × ቆܪ݋݉ ݋݃ . ܾݑ݂݂ ݁ݎݒ݋݈ (݉ )݈
ݓ݁݅݃ℎݐ݋݂ ݅ݐݏݏݑ݁(݃) ቇ × ܦ݈݅ݑ݅ݐ݋݊
Equation 5: Calculation of enzyme concentration
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2.2.6.2 Citrate Synthase (CS) Assay
CS activity was determined spectrophotometrically by following the reduction of
5,5 dithio-bis-2-nitrobenzoic acid (DTNB) (Morgan-Hughes et al., 1977). Briefly, 15
mg ground ventricular tissue was homogenised at full speed (2 × 5 seconds) using
an Ultra Turrax homogeniser (details in Section 2.2.6.1) in 1 ml extraction buffer
(100 mM imidazole, 1 mM EGTA 10 mM MgCl2, pH 7.2). Triton X-100 (1% v/v) was
added and the mixture was left on ice for 1 h. Samples were then centrifuged at
2000 g for 10 min at 4°C. Twenty micro-litres of the resultant supernatant (diluted 1
in 2) was added to 1.98ml reaction buffer containing 50 mM Tris (pH 8.1), 0.2 mM
DTNB, 0.1 mM acetyl CoA, 0.5 mM oxaloacetate and 0.05% v/v Triton X-100. The
absorbance was measured at 412 nm over 3 min. Citrate synthase activity was
calculated using an extinction coefficient of 13.6 mM-1cm-1 (Equation 5).
2.2.6.3 Medium chain Acyl-CoA dehydrogenase (MCAD) Assay
2.2.6.3.1 Preparation of Ferricene Salt
Ferricenium hexafluorophosphate was synthesised by adding 0.5 g ferrocene to 10
ml concentrated H2SO4 (Lehman et al., 1990). After 1 h, the solution was diluted to
150 ml using ultra pure water and filtered under pressure. 5 ml saturated
hexafluorophosphate monohydrate (NaPF6) was added and the mixture left on ice
for 30 min before filtering again. Prior to use, the ferricenium salt (FC+PF6) was
dissolved in 10 mM HCl and centrifuged at 3000 g for 10 min at 4°C (Lehman et al.,
1990). The supernatant was collected and the absorbance measured at 300 nm. The
concentration was then calculated using an extinction coefficient of 4.3 mM-1cm-1.
2.2.6.3.2 MCAD Assay
Frozen ventricular tissue (50 mg) was homogenised in 1 ml ice-cold buffer (50 mM
KH2PO4, 1 mM EDTA, 2 mM MgCl2 pH 7.2) at full speed for 30 seconds using an Ultra
Turrax homogeniser (details in section 2.2.6.1). Samples were centrifuged at 3000 g
for 10 minutes at 4°C. Twenty micro-litres supernatant was added to 900ml
reaction buffer containing 100 mM KH2PO4, 1 mM EDTA, 0.5 mM sodium
tetrathionate and 200 μM ferricenium hexafluorophosphate (pH 7.2). To initiate the
reaction, 50 μM octanoyl-CoA was added and the absorbance measured over 3 min
using a wavelength of 300 nm. MCAD activity was calculated using Equation 5 and
an extinction coefficient of 4.3 mM-1cm-1.
2.2.7 In Vitro Mitochondrial Function
2.2.7.1 Mitochondrial Isolation
Mitochondria were isolated using the method of(Halestrap, 198
rapidly removed, weighed, and the atria trimmed. Ventricles were g
ice-cold buffer (1:10 w/v) containing (in mM) 300 sucrose, 2 EGTA,
and homogenised at low speed (8000 rpm) for 10 s using an U
homogeniser (IKA® Labortechnik). The volume was made up to 257 | P a g e
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isolation buffer containing 5 mg/ml BSA. The suspension was centrifuged at 2000 g
for 2 min at 4°C using a Sorvall RC-5B refrigerated centrifuge (DuPont Instruments,
UK). The supernatant was removed and retained. The pellet was re-suspended in 20
ml isolation buffer with BSA (5 mg/ml), homogenised again (8000 rpm) and
centrifuged. The two supernatants were combined and centrifuged at 11,000 g for
5 min at 4°C. The resultant pellet was re-suspended in 2 ml isolation buffer with
19% v/v percol and centrifuged at 14,500 g for 20 min at 4°C. The pellet was
washed in isolation buffer and re-suspended in the respiratory activity buffer, which
comprised (in mM) 125 KCl, 20 MOPS, 10 Tris, 0.5 EGTA, 2.5 KH2PO4 and 2.5 MgCl2
(pH 7.2) to achieve a final protein concentration of 0.4 mg protein/ml, determined
using the Biorad assay.
2.2.7.2 Mitochondrial Respiration
Mitochondrial respiration was determined by measurement of oxygen consumption
using a digital oxygen recorder (Digital Model-10 Rank Brothers, Cambridge, UK),
connected to a Chart 5.5 recording system (ADInstruments, Hastings, UK). For the
calibration, sodium dithionite was added to set the oxygen baseline to zero.
Mitochondrial extract (2 ml) was added to a Clark-type oxygen electrode chamber
maintained at 25°C, and allowed to equilibrate for 5 min. State 2 respiratory
activities were measured in the presence of the NADH linked (complex I) substrates
glutamate (5 mM) + malate (1 mM), FADH2 linked (complex II) substrates succinate
(5 mM) + rotenone (1 μM) (to inhibit electron transport to and from complex I) or
palmitoyl carnitine (20 µM) + malate (2 mM), which, when oxidised, produces both
NADH and FADH2.
The transition to state 3 respiration was stimulated by the addition of ADP (0.2 mM)
and state 4 respiration reached with exhaustion of ADP. The ratio of state 3: state 4
respiration, known as the respiratory control index (RCI) indicates the coupling
between respiration and phosphorylation. ADP:O ratio was calculated from the
amount of O2 consumed by phosphorylation of 0.2 mM ADP assuming the
concentration of oxygen in an air saturated solution (at 25°C) to be 0.237
micromoles molecular oxygen per ml (Figure 2.7).
3.9 Western Blotting
ADP addedsubstrates
added
equilibration state 2
state 3
state 4Figure 2.7: Recording showing oxygen consumption of59 | P a g e
isolated mitochondria
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2.2.8 Western Blotting
Western blotting was used to determine the protein expression of PPARα, CD36
and actin in control and uraemic ventricular tissue.
I would like to thank Mrs Kathleen Bulmer for her assistance with the Western
Blotting
2.2.8.1 Preparation of Samples
Ground ventricular tissue (200 mg) was homogenised (2 × 5 seconds at full speed)
using an Ultra Turrax homogeniser (details in section 2.2.6.1) in 1 ml extraction
buffer containing 50 mM Tris (pH 7.4), 1% w/v SDS, and complete protease inhibitor
cocktail® (Roche Diagnostics, Penzberg, Germany). Samples were centrifuged at
12,100 g using a microcentrifuge (MicroCL 17R, Thermo Scientific, UK) for 10
minutes at 4˚C and the supernatant collected. Protein concentration was
determined using the BioRad assay and samples were diluted in the extraction
buffer to achieve a protein concentration of 10 μg/μl. An equal volume of SDS-PAGE
buffer (45 mM TRIS pH 7.4, 10% glycerol, 1% SDS, 2.5% 2-Mercaptoethanol blue
and Bromophenol Blue) was added to achieve a final protein concentration of 5
μg/μl. Tubes were placed in boiling water for 3 min, cooled, and stored at -20˚C
until required.
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2.2.8.2 SDS- Page
Proteins were separated using sodium dodecyl sulphate polyacrylamide gel
electrophoresis (SDS-Page). Fifty micro-grams of protein was separated using a 3%
stacking gel and 10% running gel and transferred to a nitrocellulose membrane for
2 hours at 4˚C, using a mini-transblot cell (BioRad laboratories, UK).
Following transfer, membranes were blocked for 1 h in the appropriate blocking
buffer (Table 2.3) to decrease non-specific protein binding. Membranes were
washed in 0.25% TBS-Tween 3 times for 10 min and exposed to the primary
antibody overnight at 4˚C (Table 2.3). After another 3 washes in TBS-Tween,
membranes were exposed to the secondary antibody for a further 2 h at room
temperature (Table 2.3).
2.2.8.3 Visualisation and Quantification
To visualise protein bands, membranes were exposed onto Kodak Biomax Light
films (Sigma-Aldrich, UK) using enhanced chemiluminescence (ECL) reagents
(Amersham, Uppsala, Sweden). Films were scanned and bands quantified using
scanning densitometry and ImageJ® software.
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Table 2.3: Antibody dilutions and suppliers
Supplier Dilution Dilutant Blocking Buffer
PPARα Primary Antibody Rabbit polyclonal Santa Cruz,
USA
1:1000
0.25% TBS-Tween
with 1% milk
powder
0.25% TBS-Tween
with 5% milk
powder
Secondary Antibody
Donkey Anti-Rabbit (HRP
conjugated) As above 1:4000 As above
As above
CD36 Primary Antibody Rabbit polyclonal
Abcam,
Cambridge, UK 1:6000 As above
As above
Secondary Antibody
Goat Anti- Rabbit (HRP
conjugated)
Santa Cruz,
USA
1:8000 As above
As above
Actin Primary Antibody Rabbit monoclonal New England
Biolabs
1:1000
0.1% TBS-Tween
with 5% BSA
0.1% TBS-Tween
with 5% milk
powder
Secondary Antibody Anti- Rabbit (HRP conjugated)
Santa Cruz,
USA 1:2000 As above
As above
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2.3 Statistical Analysis
Results are expressed as mean ±SEM. Statistical significance was determined using
an unpaired t test (for single mean comparisons) or two-way ANOVA, for
comparisons between all groups at all time points (using the Scheffe post-hoc test).
Pearsons analysis was used to determine the significance of bivariate correlations.
Statistical analysis was performed using SPSS software (16.0) and level of
significance was set at p < 0.05.
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Chapter 3: Characterisation of Experimental Uraemia
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3.1 Introduction
Cardiac complications account for approximately 50% of deaths in patients with
CKD (USRDS 1998). However, the exact reasons behind the elevated risk remain
unclear. Interestingly, the relative importance of arteriosclerotic disease is
diminished and those of LVH, heart failure and sudden cardiac death are increased
in patients with CKD (Foley et al., 2003). Kidney dysfunction in uraemic patients is
evident by high serum creatinine levels and declining glomerular filtration rate
(GFR) (Beddhu et al., 2003). In addition, uraemia is characterised by anaemia and
hypertension, which contribute to phenotypic cardiac alterations including LVH,
myocardial fibrosis and a reduction in capillary density.
3.1.1 Experimental Models of CKD
To understand the complex relationship between the heart and kidney, and to
reduce the high impact of cardiovascular complications on the mortality associated
with CKD, a robust and reliable experimental animal model is required. A number of
experimental models have been developed employing different strategies of renal
mass reduction or renal ischaemia to produce phenotypic alterations with a clinical
similarity to those observed in CKD patients (Hewitson et al., 2009).
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The 5/6
th nephrectomy model is a surgical procedure whereby the right kidney and
subsequently 2/3
rds of the left kidney are removed. Previous studies from this
laboratory (Raine et al., 1993, Reddy et al., 2007, Aksentijevic et al., 2009) have
shown that this model produces significant kidney dysfunction as evidenced by a 2-
fold rise in serum creatinine and urea as early as 3 weeks post-surgery, which
increases as the duration of uraemia is extended. Uraemic animals also show severe
anaemia and an increase in systolic blood pressure.
A reduction in functional kidney mass can also be achieved using the remnant
kidney model (Mishina and Watanabe, 2008). In this experimental model, ligation
of three of the four branches of the left renal artery leads to infarct of
approximately two-thirds of the kidney. Subsequently, a total nephrectomy is
performed on the right kidney. Like the 5/6
th nephrectomy model, an increase in
blood pressure and a rise in serum creatinine and urea are observed in addition to
cardiac alterations including LVH.
A model frequently used to induce CKD in mice is the surgically induced renal injury
(SIRI) model (Gagnon and Gallimore, 1988). In this model, up to 70% of the right
kidney is damaged by cauterisation followed by a total left nephrectomy 2 weeks
later. Anaemia and a doubling in serum creatinine is observed in addition to cardiac
hypertrophy (Siedlecki et al., 2009).
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The two-kidney, one-clip (2K1C) model is an experimental model of hypertension-
induced CKD, first described in dogs by Goldblatt and colleagues in 1934 (Goldblatt,
1934). This model has since been used to study hypertension and CKD in other
animals including mice (Wiesel et al., 1997), pigs (Lerman et al., 1999) and rats
(Leenen and de Jong, 1971). In this model, the left renal artery is partially
constricted by placing a clip over the renal vessels, whereas the right kidney
remains unclipped. Blood pressure is markedly increased due to the secretion of
renin from the clipped kidney, which causes the excretion of sodium and water
(pressure natriuresis) in the unclipped kidney. This results in a net fluid loss and
therefore promotes persistent stimulation of renin secretion (Helle et al., 2009).
Variations of the 2K1C model include the two-kidney, two-clip (2K2C) model where
both kidneys are clipped (Helle et al., 2009), and the one-kidney, one-clip (1K1C)
model where the left kidney is clipped and the right kidney is removed (Wiesel et
al., 1997). In these models, unlike the 2K1C model, the elevation in blood pressure
is not due to an increase in renin activity because the stenosed kidneys cannot
undergo pressure natriuresis, thus the effective blood volume remains low thereby
inhibiting renin secretion. Rather, the hypertension in these models is due to
sodium retention and volume expansion. Cardiac alterations in the 2K1C, 1K1C, and
2K2C models include LVH, fibrosis and diastolic dysfunction (Signolet et al., 2008).
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3.1.2 Erythropoietin (EPO) Treatment
Anaemia is a frequently observed characteristic in experimental models as well as
in patients with CKD (as described in Chapter 1). Interestingly, it has been shown
that haemoglobin level is an independent predictor of LVH in patients with mild to
moderate renal insufficiency (Levin et al., 1999), suggesting that anaemia may be a
key player in the development of cardiac hypertrophy and thus cardiac
complications in CKD.
During CKD, the EPO producing peritubular fibroblast cells in the kidney become
damaged, resulting in a reduction in EPO secretion and subsequent anaemia (Caro
et al., 1979, Eschbach et al., 2002). Clinical studies have shown that administering
EPO to partially or fully correct the anaemia associated with CKD induces a
regression of LVH (Silberberg et al., 1990, Hayashi et al., 2000). A reduction in LV
mass has been associated with improved survival and reduced hospitalisations in
uraemic patients (London et al., 2001). Interestingly, recent cardiac studies have
shown that EPO has direct cardioprotective actions, independent from its
haematopoietic effects, including decreasing apoptosis (Tramontano et al., 2003),
promoting neovascularisation (van der Meer et al., 2005) and reducing oxidative
stress (Li et al., 2006). Thus, the decreased EPO production during CKD may render
uraemic hearts more susceptible to injury.
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The combination of anaemia, oxidative stress and renal fibrosis during CKD
contribute to progressive tubular damage. EPO not only improves haematocrit, but
also has anti-apoptotic and antioxidant effects (as described in chapter 1).
Therefore, it is feasible that EPO administration may slow the progression of kidney
failure in CKD patients. A retrospective study found a delay in the progression of
renal dysfunction (determined by creatinine clearance) and a prolonged time to the
onset of dialysis therapy in pre-dialysis patients receiving EPO, however the
mechanisms remain unknown (Jungers et al., 2001). In support of this, Kuriyama et
al. (1997) showed improved survival rates in EPO treated CKD patients compared
with untreated patients (Kuriyama et al., 1997). Conversely, many studies have
shown that EPO treatment has little impact on the rate of renal failure progression
(Lim et al., 1990, Savica et al., 1995, The US Recombinant Human Erythropoietin
Predialysis Study Group 1991).
Clinical trials investigating the cardiovascular effects of EPO during CKD have
provided somewhat conflicting results. Surprisingly, two large clinical trials, the
CREATE and the CHOIR trail showed either no change, or increased risk of
cardiovascular events in CKD patients with EPO administration (Drueke et al., 2006,
Singh et al., 2006). EPO is associated with hypertension and elevated risk of
thrombotic events (Lee et al., 2007). It is therefore feasible that, in certain disease
states, the negative effects of EPO may abrogate the cardioprotection. Further trials
are necessary to fully clarify the impact of EPO during CKD.
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3.1.3 Objectives
 To assess the extent and progression of uraemia in 5/6 nephrectomised rats
 To determine the extent of LVH in uraemic animals, and the impact of EPO
treatment on LVH
 To investigate the impact of EPO treatment on the haematocrit and degree
of uraemia
 To examine the combined impact of uraemia and EPO treatment on blood
pressure in vivo
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3.2 Materials and Methods
3.2.1 Induction of Uraemia
Uraemia was surgically induced in male Sprague-Dawley rats as described in Section
2.2.1. Animals were studied at 3, 6, 9 and 12 weeks post-surgery.
3.2.2 Erythropoietin (EPO) Treatment
Two weeks prior to sacrifice, animals were divided into four experimental groups
 Control animals + saline (- EPO)
 Uraemic animals + saline (- EPO)
 Control animals + EPO
 Uraemic animals + EPO
EPO (Aranesp® Amgen, Cambridge, UK) was administered subcutaneously (s/c)
twice a week for two weeks at a dose of 30 μg/Kg (equivalent to approximately
3000 units/Kg) (Figure 3.1). Saline was administered s/c as a control.
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3.2.4 In Vivo Haemodynamic Analysis
I would like to thank Dr Yong Wang for his assistance with the in vivo
measurements
Twelve weeks post-surgery, animals were anaesthetised using a mixture of
isoflurane (3.5%) and oxygen (3 L/min) and maintained on 2.0% isoflurane in 1
L/min oxygen. The right carotid artery was located and exposed. A suture was tied
towards the top of the artery to create a closed circuit to allow pressure transducer
measurements. A small incision was made in the artery and a 2.0F microtipped
pressure transducer catheter inserted (Millar Instruments, Texas, USA) (Figure 3.2).
The catheter was secured in place using a suture.
aortic arch
right carotid artery
suture
catheter
Figure 3.2: Diagram of positioning of catheter
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After a short period of stabilisation, carotid artery blood pressure and heart rate
were recorded over 10 minutes using Chart 5.5 software and a PowerLab system
(4/30) with an additional blood pressure module (AD Instruments, UK). Mean
arterial pressure (MAP) was calculated using equation 6 (Wang et al., 2007).
ܯܣܲ = ܦܲ + 13 (ܵܲ − ܦܲ)
Equation 6: Calculation of MAP
DP diastolic pressure; SP systolic pressure
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3.3 Results
3.3.1 Degree of Uraemia
Serum Biochemistry
At 3, 6, 9 and 12 weeks post-induction of uraemia, serum creatinine and urea were
significantly increased in uraemic animals compared with controls (Figure 3.3 a and
b)
When the duration of uraemia was extended to 12 weeks, the serum creatinine
concentration was on average 282% higher and the serum urea concentration 448%
higher than controls, indicative of worsening kidney function.
EPO administration (30 μg/Kg twice a week for 2 weeks) had no impact on serum
creatinine or urea in either control or uraemic groups at 3, 6, 9 and 12 weeks post-
surgery (Figure 3.3 a and b), suggesting that EPO had no effect on the rate of
progression of renal dysfunction.
The serum biochemistry results highlighted 5/6th nephrectomy generated
appropriate kidney dysfunction beginning at least 3 weeks post-surgery.
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Control (+ EPO)
Uraemic (+ EPO)
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Haematocrit
Table 3.1 and Figure 3.4 show the haematocrit levels for 3, 6, 9 and 12 week control
and uraemic animals. Uraemic animals exhibited a reduced haematocrit compared
with controls, highlighting development of anaemia. The degree of anaemia did not
alter during the progression of uraemia.
EPO treatment resulted in a significant improvement in haematocrit in both
uraemic and control animals. At 3, 6, 9 and 12 weeks (with EPO treatment),
haematocrit in uraemic animals was comparable with controls.
Table 3.1: Haematocrit (%)
* p<0.05 vs. control (- EPO);
0
10
20
30
40
50
60
70
Control (n
%
3 Week
Control
(n=16)
Uraemic
(n=18)
- EPO 38 ±2 32 ±2*
+ EPO 58 ±1* 56 ±2
* p<0.05 vs. c
Ŧ p<0.05 vs. uraemic (- EPO)
6 Week 9 Week
Control
(n=14)
Uraemic
(n=13)
Control
(n=4)
Uraemic
(n=4)
38 ±1 33 ±1* 40 ±2 31 ±0*
Ŧ 59 ±2* 59 ±2Ŧ 56 ±5* 54 ±5Ŧ
Ŧ
12 Week
Control
(n=34)
Uraemic
(n=28)
42 ±1 33 ±1*
61 ±1* 62 ±1Ŧ=34)
ontrol (
*
- EPO); Ŧ p<0.05 vUraemic (n=28)
*
- EPO
+ EPOFigure 3.4: Haematocrit 12 weeks post-induction of uraemias. uraemic (- EPO)
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Spleen Weight
Figure 3.5 shows the spleen weights of uraemic and control animals at 3, 6, 9 and
12 weeks uraemia.
In untreated animals, spleen weight was the same in control and uraemic rats. Two
weeks of EPO treatment resulted in a significant increase in spleen weight which
was comparable for control and uraemic animals (Figure 3.5). In EPO treated
uraemic animals, spleen weight was increased 172%, 125%, 129% and 89% at 3, 6, 9
and 12 weeks respectively, relative to the untreated uraemic group. The mean
spleen weight was 0.84 ±0.03 g in untreated vs. 1.77 ±0.06 g (p < 0.05) in EPO
treated animals.
00.5
1
1.5
2
2.5
Contro
W
ei
gh
t(
g)
*
*
*
*F
l (n=13) Uraemic (n=15) Contro
3
*igure
l (n=22)
3.5: Spleen weight at
(*p<0.05 vs. u
Uraemic (n=22) Contro
6
*3, 6, 9 and 12 weeks uraemia
ntreated group)
l (n=4) Uraemic (n=4) Control (n=34) Uraemi
9 12
*
*c (n=28)
80 | P a g e
- EPO
+ EPO
81 | P a g e
Left Kidney Weights
During nephrectomy, approximately two-thirds of the left kidney was removed in
uraemic animals. However, at the time of sacrifice the left remnant kidney weights
in uraemic animals were similar to control animals, suggesting hypertrophy of the
remnant kidney (Table 3.2). EPO had little impact on kidney weights in control or
uraemic animals (Table 3.2).
Table 3.2: Left kidney weights
3 Week 6 Week 9 Week 12 Week
Control
(n=16)
Uraemic
(n=19)
Control
(n=22)
Uraemic
(n=22)
Control
(n=4)
Uraemic
(n=4)
Control
(n=34)
Uraemic
(n=28)
- EPO
1.7
±0.1
1.5
±0.1
1.5
±0.1
1.6
±0.1
1.3
±0.1
1.2
±0.1
1.5
±0.1
1.7
±0.1
+ EPO
1.4
±0.1
1.6
±0.1
1.5
±0.1
1.5
±0.1
1.5
±0.01
1.5
±0.2
1.5
±0.04
1.8
±0.1
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Water Content of the Lungs
At all durations of uraemia, the percentage water content of the lungs was
comparable between control and uraemic animals (Figure 3.6).
EPO administration had little impact on the percentage of water within the lungs in
control and uraemic animals at 3, 6, 9 and 12 weeks uraemia (Figure 3.6).
010
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70
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Control (n=12) Uraemic (n=15) Control (n=14)
3
%
Figure 3.6: Water content of lungs
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3.3.2 In Vivo Blood Pressure
At 12 weeks, uraemic animals had a significant increase in systolic blood pressure
(SP) and mean arterial blood pressure (MAP) compared with control animals (Figure
3.7), but similar heart rate and systolic and diastolic durations (Table 3.3).
Administration of EPO had no significant effect on the blood pressure of uraemic
or control animals (Figure 3.7).
Figure 3.7: Systolic and d
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Uraemic + EPO (n=7)
*
86 | P a g e
Max Pressure
(mmHg)
Mean Arterial
Pressure
(mmHg)
EDP
(mmHg)
Systolic
Duration (s)
Diastolic
Duration (s)
Cycle
Duration (s)
Heart Rate
(BPM)
Control
(n=7)
- EPO 116.0 ±5.3 94.9 ±4.5 84.4 ±4.2 0.072 ±0.001 0.113 ±0.006 0.185 ±0.007 327 ±11
Uraemic
(n=7)
- EPO 155.0 ±8.2* 124.9 ±6.7* 109.8 ±6.0 0.072 ±0.002 0.108 ±0.006 0.180 ±0.008 338 ±15
Control
(n=7)
+ EPO 126.8 ±3.2 106 ±3.2 95.6 ±3.2 0.074 ±0.002 0.118 ±0.004 0.191 ±0.005 315 ±8
Uraemic
(n=7)
+ EPO 153.7 ±6.9* 124.6 ±6.7 110.1 ±6.9 0.075 ±0.002 0.105 ±0.005 0.180 ±0.004 335 ±8
* p<0.05 vs. respective control
Table 3.3: In vivo blood pressure at 12 weeks post-induction of uraemia
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3.3.3 Indices of LVH
At 3 weeks uraemia (in absence/presence of EPO), there was no significant
difference in body weight and also no LVH, as evidenced by HW: BW and HW: tibia
length, compared with control animals (Table 3.4a). However, by 6 weeks, uraemic
animals showed a significant increase in HW: BW despite no change in body weight
(Table 3.4b). EPO had no impact on LVH.
At 9 weeks uraemia, no increase was observed in HW: BW or HW: tibia length
(without EPO treatment). However, this is likely due to the small sample size in this
group (Table 3.4c).
At 12 weeks, the body weights were comparable between control and uraemic
animals. Wet heart weight, HW: BW and HW: tibia length were significantly
increased in uraemic animals compared with controls (Table 3.4d and Figures 3.8 a
and b). Furthermore, HW: tibia length correlated with haematocrit (Figure 3.9
p<0.05) and also serum creatinine (Figure 3.10 p < 0.05), suggesting exacerbated
LVH with worsening kidney function. A positive correlation was also observed
between systolic blood pressure and HW: BW (Figure 3.11 p = 0.05).
Interestingly, the increase in HW: BW and HW: tibia length was lessened following
EPO treatment (Table 3.4d and Figures 3.8 a and b). HW: tibia length was increased
by 21% in uraemic animals. However, after EPO administration, HW: tibia length
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was reduced by 10% in uraemic animals. This suggests that 2 weeks of EPO
treatment induces a regression of LVH in uraemic animals.
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Table 3.3.4a: Indices of LVH at 3 weeks post-induction of uraemia
Table 3.3.4b: Indices of LVH at 6 weeks post-induction of uraemia
Body Weight (g) Wet Heart Weight (g) HW: Tibia length (g/cm) HW: Body Weight (x103)
Control
(n=16)
Uraemic
(n=19)
Control
(n=16)
Uraemic
(n=19)
Control
(n=16)
Uraemic
(n=19)
Control
(n=16)
Uraemic
(n=19)
- EPO 406.7 ±6.5 362.1 ±15.6 1.64 ±0.07 1.66 ±0.08 0.40 ± 0.02 0.41 ±0.02 4.04 ±0.18 4.61 ±0.20
+ EPO 356.0 ±9.5 339.3 ±8.8 1.64 ±0.07 1.66 ±0.09 0.41 ±0.02 0.41 ±0.02 4.63 ±0.23 4.88 ±0.22
Body Weight (g) Wet Heart Weight (g) HW: Tibia length (g/cm) HW: Body Weight (x103)
Control
(n=16)
Uraemic
(n=16)
Control
(n=16)
Uraemic
(n=16)
Control
(n=16)
Uraemic
(n=16)
Control
(n=16)
Uraemic
(n=16)
- EPO 432.0 1±0.6 401.1 ±10.9 1.57 ±0.04 1.73 ±0.02 0.36 ±0.01 0.41 ±0.02 3.65 ±0.12 4.31 ±0.11*
+ EPO 416.9 ±13.0 386.1 ±5.0 1.41 ±0.04 1.56 ±0.11 0.33 ±0.01 0.37 ±0.01 3.41 ±0.13 4.04 ±0.24*
(*p<0.05 vs. respective control)
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Table 3.3.4c: Indices of LVH at 9 weeks post-induction of uraemia
Body Weight (g) Wet Heart Weight (g) HW: Tibia length (g/cm) HW: Body Weight (x103)
Control
(n=4)
Uraemic
(n=4)
Control
(n=4)
Uraemic
(n=4)
Control
(n=4)
Uraemic
(n=4)
Control
(n=4)
Uraemic
(n=4)
- EPO 387.5 ±22.5 327.5 ±42.5 1.26 ±0.01 1.34 ±0.07 0.30 ±0.001 0.33 ±0.02 3.25 ±0.05 4.20 ±0.75
+ EPO 425.0 ±0.0 355.0 ±10.0 1.32 ±0.002 1.29 ±0.07 0.31 ±0.01 0.31 ±0.02 3.09 ±0.01 3.64 ±0.08
Body Weight (g) Wet Heart Weight (g) HW: Tibia length (g/cm) HW: Body Weight (x103)
Control
(n=59)
Uraemic
(n=50)
Control
(n=59)
Uraemic
(n=50)
Control
(n=59)
Uraemic
(n=50)
Control
(n=59)
Uraemic
(n=50)
- EPO 530.3 ±9.1 513.6 ±13.4 1.73 ±0.04 2.11 ±0.06* 0.39 ±0.01 0.47 ±0.01* 3.27 ±0.07 4.15 ±0.12*
+ EPO 516.0 ±7.7 502.3 ±14.4 1.70 ±0.04 1.91 ±0.07* 0.38 ±0.01 0.42 ±0.01Ŧ 3.30 ±0.07 3.84 ±0.14*
Table 3.3.4d: Indices of LVH at 12 weeks post-induction of uraemia
(*p<0.05 vs. respective control Ŧp<0.05 vs. untreated group)
Figure 3.8a
Figure 3.8b
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Figure 3.9: Correlation between haematocrit
and extent of LVH
(*p<0.05)
Figure 3.10: Correlation between serum creatinine
and extent of LVH
(*p<0.05)
R = 0.55*
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Figure 3.11: Correlation between SP
and extent of LVH
(*p=0.05)
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3.4 Discussion
3.4.1 Experimental Model of CKD
Surgical induction of uraemia using the 5/6 nephrectomy model produced marked
kidney dysfunction as evidenced by the increased serum creatinine and serum urea
and development of anaemia (Figures 3.3 a and b). This is in keeping with previous
results from this laboratory (Reddy et al., 2007, Aksentijevic et al., 2009), and
others (Dikow et al., 2004). Progressive renal damage leads to the retention of
creatinine and urea, thus elevated serum levels. In addition, reduced secretion of
EPO from the damaged kidney during CKD results in anaemia (Caro et al., 1979,
Eschbach et al., 2002).
EPO, which improves haematocrit, also has anti-apoptotic and antioxidant effects
and therefore it is feasible that EPO administration may slow the progression of
renal failure (Toba et al., 2009, Moon et al., 2003a). Here however, serum
creatinine and urea (which are crude measures of actual renal function) were
comparable in untreated and treated uraemic animals, suggesting that EPO had
little impact on the progression of renal failure in this model. This is consistent with
clinical observations showing that EPO does not limit CKD progression (Lim et al.,
1990, The US Recombinant Human Predialysis Study Group 1991, Savica et al.,
1995). Furthermore, the EPO-associated rise in blood pressure may actually
contribute to glomerular injury and worsening kidney function, however, this was
not observed in the present study (Lee et al., 2007, Garcia et al., 1988, Lafferty et
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al., 1991). Conversely, a number of clinical studies have shown that, in pre-dialysis
patients, the progression of renal failure (determined by creatinine clearance) was
slowed, and the time to onset of dialysis therapy prolonged with EPO treatment
(Jungers et al., 2001, Kuriyama et al., 1997).
In this study, uraemic animals had a decreased haematocrit with 3 weeks of
uraemia (Table 3.1). The anaemia observed may be in part due to decreased EPO
production from the damaged kidney, paralleling findings from uraemic patients
(Caro et al., 1979). Indeed, anaemia is present in 60-80% of patients with end stage
renal disease (ESRD) and low erythropoietin levels correlate with a reduction in
haematocrit (Hsu, 2002, Obrador et al., 2001). EPO resistance also occurs in CKD
patients, as a consequence of high circulating levels of inflammatory cytokines,
including TNFα and IL-6, potentially contributing to worsening anaemia (Goicoechea
et al., 1998, Costa et al., 2008). Low haematocrit levels are associated with an
increased risk of hospitalisation in CKD patients, and improving haematocrit
decreases risk (Xia et al., 1999, Anand et al., 2005). In this study, administration of
EPO improved haematocrit in control and uraemic animals at all stages. EPO
corrects anaemia by raising erythrocyte production and inhibiting apoptosis of
erythrocyte precursors, thereby increasing the number of circulating red blood cells
(Fisher, 2003). Coincident with the rise in haematocrit was the increased spleen
weight, observed in EPO treated animals (Figure 3.5).
The percentage water content within the lungs was comparable between uraemic
and control animals (with and without EPO treatment) at 3, 6, 9 and 12 weeks
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uraemia (Figure 3.6). This suggests that although LVH was observed at 6 and 12
weeks, uraemic hearts were in a compensatory phase but not failing. In contrast,
experimental models of post-MI heart failure have observed large increases in lung
water content, suggesting cardiac failure (Saito et al., 2002). In this regard, EPO
treatment has been shown to improve cardiac function and delay the onset of heart
failure in a murine model of post-MI heart failure (Li et al., 2006). Interestingly, a
number of clinical trials in heart failure patients have shown that EPO is safe and
well tolerated and is associated with improved exercise capacity and ejection
fraction (Mancini et al., 2003, Silverberg et al., 2001).
3.4.2 Blood Pressure
Blood pressure was determined in vivo using an arterial catheter; however, as
anaesthesia depresses heart rate and blood pressure, comparisons were not
possible with readings obtained from the conscious animal. Non-invasive
techniques, such as the tail-cuff method, have also been used for determining
blood pressure, which allows repeated measurements to be made without affecting
physiological parameters of the animal. However, limitations of this method involve
variations of blood pressure due to the restraint of the conscious animal leading to
increases in systolic blood pressure and heart rate (Kurtz et al., 2005).
At 12 weeks, uraemic animals had a markedly elevated systolic blood pressure
compared with control animals (Figure 3.7 and Table 3.3). Similar findings have
been found in previous experimental studies of CKD (Tsujimura et al., 2008,
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Kennedy et al., 2003), and are comparable to the raised blood pressures observed
in patients with renal insufficiency (Parfrey and Foley, 1999). Hypertension in this
model is present from 3 weeks post-induction of uraemia (Reddy et al., 2007).
The reasons behind the elevated blood pressure during CKD remain incompletely
understood. Activation of the renin-angiotensin-aldosterone system (RAAS) is
considered a key contributor. Indeed, a major impact on the mortality associated
with CKD has been achieved through treatment with angiotensin converting
enzyme inhibitors (ACEi) and angiontensin receptor blockers (ARB’s) (Maschio et al.,
1996). Angiotensin II acts directly on vascular smooth muscles cells as a potent
vasoconstrictor, but also has mitogenic effects (Rosenkranz, 2004). Angiotensin II
also regulates renal sodium and water absorption via release of aldosterone.
Furthermore, angiotensin II affects cardiac contractility and heart rate through
activation of the sympathetic nervous system. Interestingly, a number of studies
have shown administration of ACEi and/or ARB’s during uraemia diminished renal
fibrosis and improved proteinuria (Ikoma et al., 1991, Jaimes et al., 1998).
Moreover, several large multicentre trials have proposed renoprotective effects of
ACEi independent of their antihypertensive actions (Heart Outcomes Prevention
Evaluation Study Investigators 2000, PROGRESS trial 2001). Although a rise in blood
pressure was observed in uraemic animals here, other researchers have shown that
activation of RAAS is less pronounced in this model compared with other
experimental models of CKD which reduce functional renal mass via ligation of
renal arteries (Kobori et al., 2007).
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EPO administration did not significantly increase blood pressure in this study.
However, clinically, EPO-associated hypertension occurs in approximately one third
of CKD patients (Lee et al., 2007, Shimada et al., 2003, Faulds and Sorkin, 1989).
EPO is thought to increase blood pressure due to the expansion of blood volume
and increased blood viscosity (Miyashita et al., 2004). In addition, EPO has been
shown to raise blood pressure directly and independent of its haematopoietic
effects (Shimada et al., 2003). Heidenreich et al. (1991) demonstrated direct
vasoconstictive effects of EPO on isolated renal and mesenteric vessels in vitro
(Heidenreich et al., 1991). Furthermore, EPO promotes release of renin and
angiotensin II (Eggena et al., 1991, Brier et al., 1993), and the EPO-associated rise in
blood pressure was prevented by inhibition of the RAAS system and endothelin-1
(ET-1) blockade, highlighting a potential role for these systems (Miyashita et al.,
2004).
3.4.3 LVH
Cardiac hypertrophy was observed from 6 weeks post-surgery, increasing at 12
weeks in uraemic animals (Figure 3.8 and Table 3.4). HW: BW and HW: tibia length
were used to assess LVH in this study. HW: BW can be used to indicate LVH except
when body weight is inconsistent such as in aging, and then hypertrophy may be
overestimated. Thus, HW: tibia length becomes a better marker of LVH (Yin et al.,
1982).
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The development of LVH during CKD is complex and incompletely understood.
However, the association and persistence of haemodynamic factors, including
increased afterload (hypertension and aortic stiffening) and increased preload
(anaemia and hypervolaemia) in addition to metabolic and endocrine abnormalities
clearly play a role (London, 2003).
Clinical and experimental studies have shown that administration of
antihypertensive agents (such as ACEi) during CKD leads to a decrease in blood
pressure correlating with regression of LVH (Zoccali et al., 2004, Harnett and
Parfrey, 1994). Conversely, some experimental studies have shown that LVH
persists despite the normalisation of blood pressure (Rambausek et al., 1993).
Furthermore, LVH was observed in a mouse model of CKD without the
corresponding increase in blood pressure suggesting that development of LVH
during uraemia can be partly dissociated from the impact of hypertension alone
(Siedlecki et al., 2009).
Anaemia can also contribute to the development of LVH, independent of blood
pressure changes. A combination of decreased blood viscosity and increased flow
due to low tissue oxygenation cause an increase in demand and cardiac output
(London and Parfrey, 1997). Here, EPO improved anaemia and induced a partial
regression of LVH in uraemic animals at 12 weeks post-induction of uraemia.
Consistent with these findings, experimental (Amann et al., 2000) and clinical
studies (Silberberg et al., 1990) have demonstrated that EPO treatment is
associated with a reduction in LVH during CKD. However, controversy exists over
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the degree of anaemia correction, with some studies finding that partial, rather
than full correction of haematocrit is associated with LVH regression (Silberberg et
al., 1990, Cannella et al., 1991, Hayashi et al., 2000).
3.4.4 EPO Treatment
In the present study, darbepoietin alfa (Aranesp® Amgen, Cambridge, UK) was used,
a synthetic analogue of human recombinant erythropoietin (rhEPO). Darbepoietin
alfa is a novel erythropoiesis stimulating protein (NESP) with a higher molecular
weight, causing a three-fold longer half-life than that of rhEPO. This consequently
reduces the frequency of injections (Egrie and Browne, 2001, Macdougall et al.,
1999). Injections were given subcutaneously which results in a slower absorption;
this also allows for less frequent injections and reduces the injected volume
compared with IV administration (Halstenson et al., 1991). The dose of EPO
employed in this study (30 μg/Kg) was comparable with those used in other
experimental studies (Gao et al., 2007). The amount of EPO needed to achieve a
cardioprotective effect was originally thought to be much greater than that
required to normalise haematocrit. Gao et al. (2007) found that EPO provided a
dose-dependent cardioprotective effect with 30 μg/Kg being the optimal dose to
reduce infarct size and improve cardiac function post ischaemia/reperfusion (Gao
et al., 2007). However, a recent study by Lipsic et al. (2008) found that a low-dose
of EPO could provide cardioprotection in rat hearts without increasing haematocrit
(Lipsic et al., 2008).
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3.4.5 Conclusions
In this model, kidney dysfunction was evident from 3 weeks post-induction of
uraemia, with no evidence initially of cardiac hypertrophy. When the duration of
uraemia was prolonged to 12 weeks, animals showed anaemia, marked
hypertension and LVH. Administration of EPO improved haematocrit and lessened
cardiac hypertrophy in uraemic animals suggesting a possible beneficial effect of
EPO in this model of CKD.
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Chapter 4: In Vitro Cardiac Function and Metabolism
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4.1 Introduction
LVH is frequently observed in CKD patients (Foley et al., 1995). Although initially
beneficial in terms of reducing wall tension and preserving function, the
hypertrophied heart is accompanied by a plethora of intracellular changes, which
produce a pathophysiological phenotype, leading ultimately to heart failure (Levy et
al., 1990). One such change is remodelling of metabolism involving a switch in
substrate preference away from fatty acid oxidation (FAO) towards glucose
utilisation, which may contribute to the cardiac dysfunction observed in uraemic
patients (Chapter 1) (Barger and Kelly, 1999, Osorio et al., 2002, Sambandam et al.,
2002).
4.1.1 Determination of In Vitro Cardiac Function
The assessment of cardiac function in vitro has allowed researchers to study the
isolated heart in a variety of experimental models, including LVH and uraemic
cardiomyopathy. A number of perfusion systems have been developed including
the isovolumic Langendorff and the working-heart preparations, which allow the
simultaneous measurement of cardiac function and oxygen consumption (Ross,
1972).
The Langendorff preparation was first described by Oscar Langendorff in 1895 and
has since been developed and modified by a number of researchers (Opie, 1965,
Bleehen and Fisher, 1954). In this perfusion method, the aorta is cannulated and
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the heart retrogradely perfused. The perfusion medium is prevented from entering
the heart by the aortic valve, and thus travels through the coronary arteries under
hydrostatic pressure. This method has been used for well over a century and
remains a standard technique for assessing in vitro cardiac function and
metabolism. The Langendorff preparation is frequently used as it is technically
easier and requires less complex equipment than other perfusion methods (Ross,
1972). However, the ventricle undergoes little or no filling and thus no external
work is performed. This was overcome by the introduction of the left-sided
working-heart preparation first described by Neely and Morgan (1967). In this
method, the left atrium is also cannulated, and after a brief period of retrograde
perfusion, the flow is reversed and the perfusion medium enters the left ventricle
and is ejected out of the cannulated aorta (Neely et al., 1967). Interestingly, it has
been shown that although the Langendorff perfused heart undergoes no external
work (i.e. the emptying and filling of the ventricles), this has little impact on
metabolism and function when compared with working-heart preparations.
4.1.2. Metabolic Remodelling
LVH is present in up to 75% of CKD patients (Foley et al., 1995). Cardiomyocytes
hypertrophy in response to haemodynamic overload, which helps reduce wall
tension and preserve systolic function (Grossman, 1980). Although the early stages
of LVH are physiologically beneficial, many of the adaptations become limited and
thus maladaptive, initiating the transition to cardiac dysfunction and failure (Levy et
al., 1990, Seymour, 2003b). In response to pathophysiological stimuli, the
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hypertrophied heart is not simply an enlarged heart. Instead, LVH is accompanied
by a number of intracellular changes. One such change is the altered profile of
substrate utilisation, known as metabolic remodelling.
In the healthy adult heart, most of the ATP is derived from fatty acid oxidation, with
a smaller contribution from glucose and lactate. Experimental models of volume-
overload (el Alaoui-Talibi et al., 1992) and pressure-overload (Allard et al., 1994,
Akki et al., 2008) cardiac hypertrophy have shown a switch in substrate usage from
fatty acids, towards glucose utilisation (Barger and Kelly, 1999, Osorio et al., 2002,
Sambandam et al., 2002). The change in substrate preference is consistent with a
re-expression of the foetal phenotype and may initially represent a beneficial
adaptation in LVH. Indeed, if fatty acid oxidation is reduced, then glucose oxidation
would increase via the Randle cycle, which could potentially improve coupling
between glycolysis and glucose oxidation therefore decreasing the glycolytic
production of lactate and protons. Moreover, ATP production from glucose is more
oxygen efficient than from fatty acids, owing to more oxygen atoms already present
on the glucose molecule, therefore the shift towards glucose utilisation may be
important to reduce oxygen consumption and sustain function during LVH
(Taegtmeyer, 1986).
In the longer term however, this remodelling may result in complications including
energy depletion (Leone et al., 1999, Seymour and Chatham, 1997), thereby
initiating the transition to heart failure.
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Little research has been undertaken to determine the profile of myocardial
substrate utilisation in uraemia. However, given that LVH is frequently observed in
experimental models of CKD and in the clinical scenario, it is feasible that the
metabolic remodelling associated with LVH also occurs in the uraemic heart and
may eventually contribute to cardiac dysfunction and failure. Furthermore,
experimental models of CKD have a decrease in the myocardial phosphocreatine
(PCr)/ATP ratio suggesting that the uraemic heart is depleted of energy reserves,
potentially reflecting altered myocardial energy metabolism (Raine et al., 1993).
4.1.3 Objectives
In this chapter, in vitro cardiac function and the extent of metabolic remodelling
were assessed in experimental uraemia. The impact of EPO therapy was also
examined in the experimental model. Specifically the aims of this chapter were
 To determine the profile of substrate utilisation in uraemic and control
hearts using 13C NMR
 To examine the impact of chronic EPO administration on cardiac metabolism
 To determine the effect of uraemia and chronic EPO treatment on the
activities of key mitochondrial metabolic enzymes
 To assess the impact of acute and chronic EPO administration on in vitro
cardiac function and efficiency using the Langendorff perfusion method in
uraemic and control hearts
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 To identify the effects of increasing cardiac workload on untreated and EPO
treated uraemic and control hearts
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4.2 Materials and Methods
4.2.1 Effects of Acute EPO Administration
To determine the effect of acute EPO administration on in vitro cardiac function,
control hearts from male Sprague-Dawley rats (weighing approximately 400 g)
were perfused with K-H buffer (as described in Section 2.2.4) containing EPO at the
following concentrations 0.006 μg/ml, 0.03 μg/ml and 0.06 μg/ml (equivalent to 1,
5 and 10 U/ml respectively) (Figure 4.1a). Oxygen consumption and cardiac
efficiency were calculated as described in Section 2.2.4.3.
4.2.2 Effects of Uraemia and Chronic EPO Administration
Uraemia was induced surgically in male Sprague-Dawley rats and animals
maintained for up to 12 weeks post-surgery with respective sham operated rats as
a control (details provided in Section 2.2.1).
Animals were divided into 4 experimental groups
 Control animals + saline (- EPO)
 Uraemic animals + saline (- EPO)
 Control animals + EPO
 Uraemic animals + EPO
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EPO (30 µg/Kg) or equal volumes of saline were administered by subcutaneous
injection twice a week for 2 weeks prior to experiments (Section 3.3.2).
Hearts were isolated from the 4 groups of rats and perfused according to the
protocol given in Figure 4.1b (details of perfusion provided in Section 2.2.4). To
determine the effect of increasing cardiac work, hearts were initially perfused using
buffer containing 1.25 mM [Ca2+], which was increased to 2.5 mM [Ca2+]. To
investigate myocardial metabolism, K-H buffer was switched to an identical buffer
containing 13C labelled substrates (Figure 4.1b) and substrate utilisation determined
using 13C NMR (as described in Section 2.2.5).
4.2.3 Mitochondrial Enzyme Activity
Pyruvate Dehydrogenase (PDH), Citrate Synthase (CS) and Medium-Chain Acyl-CoA
Dehydrogenase (MCAD) activities were determined as described in Sections 2.2.6.1,
2.2.6.2 and 2.2.6.3, respectively.
Figure 4.1a: Protocol for acute EPO administration
Figure 4.1b: Protocol for chronic EPO treatment
t=10 t=30 t=75
K-H buffer with the following
Equilibration Normoxia Normoxia
Normoxia
K-H buffer containing 3% BSA
t=0 t=20 t=50 t=65 t=80 t=95
EPO Dose Response
Equilibration 0.006 μg/ml 0.03 μg/ml 0.06 μg/mlK-H buffer (1.25 mMt=0CaCl2)Figure 4.1: Perfusion Protocols
modificatio
2.5 mM Ca
5 mM 1-13C
0.3 mM U-110 | P a g e
ns
Cl2
glucose (100%)
13C sodium palmitate (50%)
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4.3 Results
4.3.1 Effect of Acute EPO Administration
In vitro myocardial function and efficiency were not significantly altered following
acute EPO administration regardless of the EPO concentration used (Table 4.1).
EPO
(µg/ml)
LVDP
(mmHg)
RPP ×103
(mmHg/bpm)
MVO2
(µmol/ g wet heart
weight/ min)
Cardiac Efficiency
×103 (mmHg/ µmol/ g
wet heart weight)
0
(n=4) 128 17.3 32.2 5.5 0.87 0.1 43.0 3.0
0.006
(n=4) 115 19.5 31.8 3.0 0.87 0.1 40.5 4.5
0.03
(n=4) 110 17.6 30.5 4.3 0.89 0.2 39.1 4.5
0.06
(n=4) 115 17.1 30.4 5.9 0.86 0.1 38.5 4.0
Table 4.1: Effects of acute EPO administration
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4.3.2 Effects of Uraemia and Chronic EPO Administration
Three Week
At 3 weeks uraemia, LVDP, RPP and cardiac contractility (dP/dtmax/min) were
comparable to control hearts and unaffected by chronic EPO administration (Table
4.2 and Figure 4.2). Consequently, there were no significant differences in oxygen
consumption (MVO2) or cardiac efficiency between untreated and EPO treated
control and uraemic hearts (Figures 4.3 and 4.4).
Table 4.2: In Vitro cardiac function at 3 weeks uraemia
Systolic Pressure
(mmHg)
LVDP
(mmHg)
(dP/dt)max
(mmHg/s)
(dP/dt)min
(mmHg/s)
Control
(n=6)
- EPO 172 ±20 170 ±19 8143 ±571 -5273 ±242
Uraemic
(n=7)
- EPO 188 ±17 186 ±17 7549 ±406 -4683 ±391
Control
(n=10)
+ EPO 199 ±16 199 ±15 7329 ±517 -4131 ±216
Uraemic
(n=11)
+ EPO 213 ±21 212 ±20 7834 ±678 -4339 ±347
Figure 4.2: Rate pressure product at 3 weeks post
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4.3: MVO2 at 3 weeks post-induction of uraemia
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Figure 4.4: Cardiac efficiency in uraemia
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Six Week
At 6 weeks uraemia, hearts perfused with 1.25 mM calcium showed little
differences in function, MVO2 or cardiac efficiency compared with controls, and
were unaffected by chronic EPO administration (Table 4.3).
Increasing buffer [Ca2+] from 1.25 mM to 2.5 mM, resulted in a marked increase in
LVDP and RPP (Table 4.3 and Figure 4.5), however, RPP and cardiac efficiency
remained comparable between control and uraemic hearts (Figures 4.4, 4.5 and
4.6).
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Table 4.3: In Vitro cardiac function at 6 weeks uraemia
1.25mM calcium
Systolic Pressure
(mmHg)
LVDP
(mmHg)
(dP/dt)max
(mmHg/s)
(dP/dt)min
(mmHg/s)
Control
(n=5)
- EPO 125 ±11 123 ±11 4822 ±347 -2629 ±199
Uraemic
(n=5)
- EPO 119 ±10 118 ±11 4515 ±362 -2435 ±182
Control
(n=5)
+ EPO 137 ±9 137 ±8.9 5101 ±262 -2816 ±174
Uraemic
(n=7)
+ EPO 137 ±11 136 ±10 5024 ±349 -2823 ±150
2.5mM calcium
Systolic Pressure
(mmHg)
LVDP
(mmHg)
(dP/dt)max
(mmHg/s)
(dP/dt)min
(mmHg/s)
Control
(n=5)
- EPO 176 ±11 174 ±11 6976 ±352 -3879 ±247
Uraemic
(n=5)
- EPO 171 ±12 171 ±12 6817 ±403 -3924 ±272
Control
(n=5)
+ EPO 186 ±13 184 ±13 7084 ±536 -4019 ±212
Uraemic
(n=7)
+ EPO 198 ±14 198 ±14 7430 ±474 -4566 ±218
Figure 4.5: Rate pressure product at 6 weeks post
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4.6: MVO2 at 6 weeks post-induction of uraemia
Uraemic (n=12) Contol (n=10) Uraemic (n=12)
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Twelve Week
Twelve weeks of uraemia did not modify LV developed pressures, contractility or
efficiency when perfused using K-H buffer containing 1.25 mM [Ca2+], and were
unaffected by chronic EPO treatment (Table 4.4 and Figure 4.7).
When hearts were perfused using 2.5 mM [Ca2+], LVDP and RPP significantly
increased compared with hearts perfused using 1.25 mM [Ca2+]. Contractility (as
evidenced by dP/dtmax/min) was the same in control and uraemic hearts (Table 4.4).
Furthermore, MVO2 and cardiac efficiency were unchanged in uraemic compared
with control hearts (Figures 4.4 and 4.8).
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Table 4.4: In Vitro cardiac function at 12 weeks uraemia
1.25mM calcium
Systolic Pressure
(mmHg)
LVDP
(mmHg)
(dP/dt)max
(mmHg/s)
(dP/dt)min
(mmHg/s)
Control
(n=8)
- EPO 105 ±3 102 ±3 3756 ±260 -2169 ±175
Uraemic
(n=7)
- EPO 122 ±11 119 ±11 4243 ±355 -2424 ±189
Control
(n=8)
+ EPO 105 ±7 105 ±7 3990 ±183 -2211 ±136
Uraemic
(n=6)
+ EPO 117 ±11 117 ±11 4378 ±253 -2452 ±203
2.5mM calcium
Systolic Pressure
(mmHg)
LVDP
(mmHg)
(dP/dt)max
(mmHg/s)
(dP/dt)min
(mmHg/s)
Control
(n=8)
- EPO 136 ±6 135 ±5 5275 ±244 -2995 ±169
Uraemic
(n=7)
- EPO 160 ±11 156 ±10 5808 ±252 -3467 ±129
Control
(n=8)
+ EPO 140 ±9 139 ±9 5382 ±236 -3101 ±139
Uraemic
(n=6)
+ EPO 163 ±11 162 ±11 6279 ±318 -3808 ±224
Figure 4.7: Rate pressure product at 12 weeks post
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4.8: MVO2 at 12 weeks post-induction of uraemia
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4.3.3 Cardiac Metabolism
The relative contributions of substrates to oxidative metabolism were assessed at 3,
6 and 12 weeks post-induction of uraemia (data given in Figures 4.9 a-c).
By 3 weeks, the contributions of palmitate and glucose to oxidative metabolism
were unchanged in all 4 groups (Figure 4.9a). At 6 weeks, there was a reduction in
the contribution of palmitate to oxidative metabolism in uraemic hearts compared
with controls (27.5 ±1.9% vs. 20.0 ±1.5% p<0.05), consistent with the onset of LVH
(see results from Section 3.3.3). Accordingly, there was an increase in glucose and
unlabelled substrate utilisation in uraemic compared with control hearts (Figure
4.9b).
At 12 weeks, there were no significant differences in the contribution of substrates
to oxidative metabolism between any of the groups (Figure 4.9c).
Figure 4.9a: Contribution of
Figure 4.9b: Contribution of
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Figure 4.9c: Contribution of 13C labelled substrates to oxidative metabolism at
12 weeks uraemia
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4.3.4 Mitochondrial Enzyme Activities
At 3 and 12 weeks, MCAD activity was similar in uraemic and control hearts
irrespective of EPO treatment (Figures 4.10 and 4.11).
PDH activity at 12 weeks post-induction of uraemia is given in Figure 12 (a and b).
Total PDH was unaltered in all 4 groups (data not shown). The amount of PDH in the
active form (Figure 4.12a) was also unchanged resulting in comparable PDHa/PDHt
ratios (Figure 4.12b).
Cardiac CS activity was similar between control and uraemic animals at both 6 and
12 weeks post-induction of uraemia (Table 4.5).
Table 4.5: CS activity at 6 and 12 weeks post-induction of uraemia
6 week 12 week
Control
(n=8)
Uraemic
(n=8)
Control
(n=9)
Uraemic
(n=9)
- EPO 73.5 ±1.8 75.1 ±8.5 95.0 ±9.6 96.5 ±6.4
+ EPO 77.0 ±4.6 83.1 ±6.9 94.5 ±5 87.1 ±5.6
Figure 4.10: MCAD activity at 3 weeks post
Figure 4.11: MCAD activity at 12 weeks post
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4.4 Discussion
EPO perfusion had little impact on in vitro cardiac function or efficiency in control
hearts. Uraemic rat hearts demonstrated preserved in vitro cardiac function,
consistent with a compensatory phase of LVH, which was unchanged following
chronic EPO administration. At 6 weeks post-induction of uraemia, contribution of
palmitate to myocardial oxidative metabolism was decreased compared with
control hearts, which parallels observations from studies using the hypertrophied
heart.
4.4.1 Effects of Acute EPO Administration
Acute EPO administration had little impact on cardiac function in control hearts
irrespective of the dose (Table 4.1). This is consistent with previous studies, using
similar EPO doses, which showed that, under baseline conditions, EPO had no effect
on cardiac function in isolated perfused hearts (Wright et al., 2004). In contrast,
Piuhola et al. (2008) observed a dose-dependent increase in ventricular developed
pressure with acute EPO administration (1-3 U/ml) in the perfused rat heart
(Piuhola et al., 2008). EPO has been shown to exert an acute cardioprotective effect
after a period of ischaemia, by reducing apoptotic cell death and improving function
during reperfusion (Wright et al., 2004). Bullard et al (2005) demonstrated that the
protective effect of EPO during ischaemia/reperfusion was abolished in the
presence of the P13K inhibitors wortmannin and LY294002 and the ERK 1/2
inhibitor U0126, suggesting that the beneficial action of acute EPO treatment is
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mediated via activation of the RISK (Reperfusion Injury Salvage Kinase) pathway
(Bullard et al., 2005).
Acutely administered EPO mediates a number of signalling pathways which can
potentially directly modify myocardial function. In rats with renal failure, and in
post-hypoxic mice, erythropoietin treatment improved cardiac contractility via
modulation of Na+/K+ ATPase (Sterin-Borda et al., 2003, Wald et al., 1995). This
suggests that EPO may act as a positive inotrope to improve function, however, this
was not observed in the present study. EPO may also mediate contractility and
acute cardiac function through its effects on intracellular calcium handling. EPO-
EPOR interaction leads to phosphorylation of phospholipase C γ-1 (PLC γ-1), which
translocates and binds to EPOR. This, in turn, results in the hydrolysis of
phosphatidylinositol 4,5 bisphosphate (PIP2) forming inositol 1,4,5-triphosphate
(IP3), and consequently liberates Ca
2+ from intracellular stores, altering force of
contraction (Marrero et al., 1998). In support of the involvement of EPO in calcium
handling, a number of studies have shown increased intracellular [Ca2+] with EPO
treatment (Vaziri et al., 1996, Vaziri et al., 1995, Neusser et al., 1993).
4.4.2 Effects of Uraemia and Chronic EPO Administration
At 3 weeks uraemia, there was little change in cardiac function or efficiency
between the four groups, in keeping with previous findings in the laboratory (Reddy
et al., 2007) (Table 4.2, Figures 4.2-4.4). At 6 and 12 weeks post-induction of
uraemia, no differences in function or efficiency were observed when hearts were
129 | P a g e
perfused with 1.25 mM [Ca2+]. When the buffer calcium concentration was
increased to 2.5 mM, LVDP and RPP increased proportionally in all groups (Tables
4.3-4 and Figures 4.4-8). Raising the calcium concentration increases calcium influx
into the cardiomyocyte, thereby increasing the force of contraction and contractile
demand (Gwathmey et al., 2007).
At both 6 and 12 weeks, no significant differences were observed in RPP or dP/dt
(max and min) in uraemic hearts compared with respective controls (Table 4.4).
Uraemia is associated with hypertension (Section 3.3.2), which may result in a rise
in ventricular developed pressure in order to exceed the pressure in the artery, thus
maintaining cardiac output, however, this was not observed in the present study.
These results are consistent with the view that 12 weeks of uraemia corresponds to
a compensatory phase of LVH. With progression of uraemia and sustained insult
(such as prolonged pressure or volume overload), the heart may not compensate,
thus contractility and LVDP fall and cardiac dysfunction and failure would ensue.
In contrast to the findings from this study, Raine et al. (1993) used a working heart
preparation to show impaired cardiac function at 4 weeks post-induction of
uraemia. However, in addition to the different perfusion methods used, Raine et al.
induced renal dysfunction via a two-stage 5/6th nephrectomy and could therefore
have produced a more severe model of uraemia than in this study (Raine et al.,
1993). Clinical studies also suggest that impairment of cardiac function occurs early
in the progression of renal failure (Parfrey et al., 1996, Pehrsson et al., 1984).
However, it is difficult to extrapolate results from clinical studies to the
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experimental setting, due to the existence of comorbidities, such as diabetes, which
are frequently present in CKD patients. McMahon et al. (2002) demonstrated
impaired relaxation (evidenced by prolonged calcium transients) in isolated
cardiomyocytes from uraemic hearts in the presence of 4 mM [Ca2+] (McMahon et
al., 2002). Thus, a combination of uraemia with additional stresses such as elevated
[Ca2+] or increased pacing may unmask dysfunction in uraemic hearts.
4.4.3 Myocardial Metabolism
In this study, at 3 weeks uraemia, no change in myocardial metabolism was
observed. However, by 6 weeks, the contribution of palmitate to oxidative
metabolism decreased in uraemic hearts with a corresponding rise in contributions
from glucose and unlabelled substrates.
The decrease in palmitate utilisation may result in decreased MVO2 thus sustaining
cardiac function in uraemic hearts as glucose utilisation is more oxygen-efficient
than fatty acid oxidation. For one mole of oxygen consumed, glucose yields 6.3
moles of ATP, compared with fatty acids which produce only 5.7 moles of ATP from
the same amount of oxygen (Taegtmeyer, 1986).
Few studies have investigated the metabolic profile of the uraemic heart. Reddy et
al. (2007) showed little alterations in substrate utilisation at 3 or 6 weeks uraemia
when hearts were perfused using 1.25 mM calcium. In this study, at 6 and 12
weeks, uraemic animals demonstrated marked LVH compared with controls, and
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the altered profile of substrate oxidation is consistent with findings from models of
both pressure (Allard et al., 1994, Sambandam et al., 2002, Akki et al., 2008) and
volume overload hypertrophy (el Alaoui-Talibi et al., 1992). Experimental models of
LVH have shown the metabolic remodelling to reflect a re-expression of the foetal
gene programme. After birth, the up-regulation of fatty acid oxidation (FAO)
parallels mitochondrial development and an increased expression of the regulatory
transcription factor PPARα.
During hypertrophy, expression of myocardial PPARα is reduced, coinciding with a
reduction in the expression of FAO enzymes including carnitine palmitoyl
transferase 1 (CPT1) and MCAD (Barger et al., 2000). Interestingly, in this study,
MCAD activity was not significantly altered during uraemia despite the decrease in
FAO.
Recent experimental studies have shown that in addition to decreased PPARα
expression, the expression of PGC1α is also down-regulated and may contribute to
diminished FAO in chronic heart failure (Garnier et al., 2003). Interestingly, PGC-1α
mRNA is decreased when Akt is over expressed (Cook et al., 2002) and, given that
uraemia is associated with high levels of angiotensin II, which activate the Akt
pathway, this may reduce PGC-1 and thus account for decreased FAO in this model
(Perlman et al., 2004). Supporting the role of angiotensin II in metabolic
remodelling, prolonged exposure of cultured adult rat cardiomyocytes to
angiotensin II directly reduced palmitate oxidation. Interestingly, this metabolic
adaptation was blocked by inhibition of TNFα (Pellieux et al., 2009). Moreover, in a
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separate study, Pellieux et al. (2006) observed decreased mRNA expression of key
proteins involved in β-oxidation in the myocardium of mice over-expressing
angiotensinogen, a precursor for angiotensin II. However, a reduction in FAO was
only observed after the onset of heart failure, highlighting that in this particular
model, the decline in palmitate oxidation was a consequence, rather than a cause
of heart failure (Pellieux et al., 2006).
EPO treatment is associated with RAAS activation and elevated angiotensin II levels,
potentially contributing to a rise in blood pressure (Brier et al., 1993, Eggena et al.,
1991). It is therefore feasible that EPO may further reduce FAO via its effect on
angiotensin II. However, this was not observed in the present study.
It remains unclear whether metabolic remodelling characteristic of LVH is a
beneficial adaptation to sustain function or the trigger for the onset of heart failure.
As previously mentioned, glucose utilisation is more oxygen efficient compared
with fatty acids for ATP production (Taegtmeyer, 1986). Moreover, increasing
glucose oxidation can improve coupling between glycolysis and glucose oxidation
therefore reducing lactate and proton (H+) accumulation. This notion has been
supported by a number of studies whereby increasing glucose oxidation (either
directly, or indirectly via FAO reduction) improves function (McCormack et al.,
1996). Furthermore, Young et al. (2001) demonstrated that inappropriate
reactivation of PPARα and increased FAO exacerbated dysfunction during cardiac
hypertrophy (Young et al., 2001a). This suggests that the switch to glucose
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oxidation may be essential for sustaining cardiac function in pathophysiological
LVH.
In contrast, experimental models of heart failure have demonstrated improved
cardiac function with increased PPARα activation (Brigadeau et al., 2007, Labinskyy
et al., 2007). This implies that the reduction in FAO in heart failure may contribute
to dysfunction. Indeed, reduced oxidation of lipids and accumulation of lipid
intermediates may result in lipotoxicity. Furthermore, inhibition of PDH by fatty acyl
components (as described in Chapter 1) limits the entry of glucose in to the TCA
cycle. This may render the uraemic heart energy starved. However, the portion of
PDH in the active form in this study was not decreased in uraemic hearts. Increasing
the duration or severity of uraemia may result in inhibition of PDH and thus may
render the uraemic heart ‘inflexible’ to up-regulate glucose oxidation resulting in
energy starvation. Indeed, diminished energy stores (indicated by reduced PCr/ATP
ratio), have been observed in an experimental model of uraemia (Raine et al.,
1993). Moreover, clinical studies have shown a progressive decline in PCr/ATP ratio
in CKD patients with increased duration on peritoneal dialysis (Ogimoto et al.,
2003).
4.4.4 Conclusion
In conclusion, despite LVH and systemic hypertension being prominent features at
both 6 and 12 weeks uraemia, in vitro cardiac function was preserved, highlighting a
compensatory phase of hypertrophy. Palmitate utilisation was decreased at 6
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weeks in uraemic hearts consistent with the metabolic remodelling observed in
models of LVH. This remodelling may initially be a beneficial adaption to sustain
function, however, in the longer term may be a precursor for the transition from
compensatory LVH into dysfunction and heart failure.
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Chapter 5: In Vivo Cardiac Function and Fibrosis
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5.1 Introduction
The uraemic heart is characterised by phenotypic alterations including LVH. Initially,
an increase in cardiomyocyte size normalises wall tension and allows maintenance
of cardiac function (Grossman, 1980). However, persistent elevations in wall stress
will eventually exceed the hearts ability to compensate and cardiac failure will
ensue (Levy et al., 1990). Coupled with increased cell size is the expansion of
extracellular matrix (ECM). As pathophysiological LVH progresses, a
disproportionate accumulation of collagen occurs, known as cardiac fibrosis, which
contributes to dysfunction and may serve as a contributing mechanism to the onset
of heart failure.
5.1.1 Cardiac Fibrosis
Myocardial ECM, comprised primarily of collagen, provides a dense structural
network which is vital for structural integrity and force transmission (Weber et al.,
1994). An increased amount of collagen within the heart is characteristic of many
disease states including LVH (Gao et al., 2005), hypertension (Zhai et al., 2008) and
uraemic cardiomyopathy (Amann and Ritz, 1996).
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There are two major types of cardiac fibrosis, reparative and reactive. Reparative
(or replacement) fibrosis involves increased deposition of collagen to replace
necrotic cells and exists as microscopic scarring. Reactive fibrosis is the
accumulation of collagen either around vessels (perivascular fibrosis) or diffusely
between cardiomyocytes (interstitial fibrosis) (Weber, 1989).
The development of fibrosis is under the control of a number of factors including
transforming growth factor β (TGF-β) and angiotensin II, the up-regulation of which
are associated with the onset of fibrosis (Weber and Janicki, 1989, Kuwahara et al.,
2002). Furthermore, decreased collagen breakdown may also play a role in the
development of cardiac fibrosis. Collagen degradation is mediated by the enzymes
collagenase and matrix metalloproteinases (MMPs). In the spontaneously
hypertensive rat (SHR), cardiac fibrosis was accompanied by decreased collagenase
activity contributing to accumulation of collagen and diminished collagen
breakdown (Varo et al., 2000). Interestingly, in cultured adult rat cardiac fibroblasts,
angiotensin II inhibited collagenase activity, which may be important as elevated
angiotensin II is characteristic of CKD, and thus may be a factor in the accumulation
of collagen within the uraemic heart (Brilla et al., 1994).
In addition to the increased quantity of collagen, alterations in the relative
proportions of type I and type III collagens play an important role in the
development of ventricular stiffness. Type I collagen typically forms thick fibres
(average diameter 75 nm) and is associated with high tensile strength. Conversely,
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type III collagen generally forms thinner strands (average diameter 45 nm) which
provide elasticity (de Souza, 2002). Experimental studies have confirmed increased
cardiac stiffness with a raised collagen type I/type III ratio (Yamada et al., 2009). An
increase in collagen type I relative to type III has been observed in patients with
chronic heart failure (Bishop et al., 1990) and dilated cardiomyopathy
(Marijianowski et al., 1995). Furthermore, observations from the uraemic heart also
show elevated quantities of type I collagen (Rabkin et al., 2008).
As well as the increased amount of collagen and change in the relative proportions
of collagen types, increased cross-linking of collagen fibres contributes to reduced
ventricular compliance. Jalil et al. (1989) identified increased cross-linking forming a
dense network of fibrillar collagen in the pressure-overloaded rat heart (Jalil et al.,
1989). Furthermore, in the spontaneously hypertensive rat (SHR), the improvement
in myocardial stiffness with hydralazine therapy was associated only with improved
collagen solubility whereas the total collagen amount and collagen type I/type III
remained unchanged (Norton et al., 1997).
Animal models of CKD (Amann and Ritz, 1996, Kalk et al., 2007, Mall et al., 1988)
and post-mortem studies (Mall et al., 1990) have revealed extensive cardiac fibrosis
in uraemia. Experimental studies using the 5/6th nephrectomy model have
identified enhanced activation and proliferation of cardiac interstitial fibroblasts in
uraemia (Mall et al., 1988, Amann and Ritz, 1997, Amann et al., 1994). Interestingly,
fibrosis has been shown to occur in experimental uraemia despite normalisation of
blood pressure and LVH (Piotrkowski et al., 2009, Mall et al., 1988).
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The presence of myocardial fibrosis has functional consequences including
ventricular arrhythmias and reduced ventricular compliance (Saito et al., 2007,
Varnava et al., 2001). Moreover, the deposition of collagen fibres between
capillaries and myocytes increases the oxygen diffusion distance and contributes to
oxygen starvation, enhancing the susceptibility of the uraemic heart to ischaemic
injury. Importantly, an increase in collagen within the myocardium impedes
relaxation of the ventricles leading to diastolic dysfunction, which is frequently
observed in patients with renal insufficiency (Otsuka et al., 2009).
5.1.2 In Vivo Cardiac Function
Many studies use in vitro methods, including perfused heart preparations (Chapter
4), to assess dysfunction in experimental models. However, in vivo methods of
monitoring cardiac function have the advantage of determining function under the
conditions of hormonal and haemodynamic influences as part of the cardiovascular
system. Echocardiography is the most widely used non-invasive method for
evaluating left ventricular function (including left ventricular shape and size) in
patients (Mohrman and Heller, 2006). However, recording and interpreting
echocardiographs require extensive training and therefore reliability and quality of
results are operator dependent. In addition, many of the functional parameters are
derived from calculations based on simplified assumptions, which may introduce
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error. MRI (magnetic resonance imaging) overcomes many of these drawbacks
(Guttman et al., 1997), however MRI is a complex and expensive technique, and
cannot be used on critically ill patients so therefore it is not currently used as a
routine diagnostic tool in clinical practice. Using an arterial catheter, inserted into
the left ventricle allows accurate measurement of cardiac function in vivo. This
highly invasive terminal technique is frequently used for determining cardiac
function in small animals for research purposes.
5.1.3 Objectives
In this chapter, the combined impact of uraemia and chronic EPO treatment on
cardiac function was assessed, in addition to the extent of fibrosis in uraemic heart.
Specifically, the aims of this chapter were
 To determine the impact of uraemia and EPO administration on cardiac
function in vivo
 To identify the extent of myocardial fibrosis in uraemic hearts and the
impact of chronic EPO treatment on collagen deposition
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5.2 Methods
5.2.1 Induction of Uraemia and EPO treatment
Uraemia was induced surgically in male Sprague-Dawley rats (details provided in
Section 2.2.1). Animals were divided in to 4 experimental groups; EPO was
administered as described in Section 3.3.2.
 Control animals + saline (- EPO)
 Uraemic animals + saline (- EPO)
 Control animals + EPO
 Uraemic animals + EPO
5.2.2 Determination of In Vivo Cardiac Function
At 12 weeks post-induction of uraemia, cardiac function was determined in vivo
using an arterial Millar catheter as described in Section 3.2.5 (Wang et al., 2007).
After measurement of blood pressure in the right carotid artery, the catheter was
advanced through the aortic arch and into the left ventricle. Successful entry into
the ventricle was confirmed by a drop in end diastolic pressure (DP) (Figure 5.1).
Figure 5.1: Recording of in vivo a) arterial blood pressure a
b) left ventricular pressure of an anaesthetised rat
RPP was calculated from the product of HR × LVDP (as a measure of
as detailed in Section 2.2.4.2.
5.2.3 Histology of Uraemic Hearts
Twelve weeks post-induction of uraemia, hearts were removed from
of animals, rinsed in K-HB buffer and mounted onto a cork platform
Tek OCT® compound (Williams et al, 1999). The whole heart was tra
pre-cooled 2-methyl-butane and placed in liquid nitrogen prior to stor
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Five 12 μm thick sections were taken from the mid-papillary region of each heart,
using a cryostat microtome (Microm HM 505 E Cryostat, Thermo Scientific,
Walldorf, Germany) and stained for structure using haematoxylin and eosin (H & E)
stain. Briefly, sections were fixed using formal saline and stained with Delafield’s
haematoxylin for 5 minutes, prior to rinsing under running water for 10 minutes.
Sections were dehydrated using a series of ascending ethanol dilutions, and
subsequently stained using eosin for 1 minute, before clearing in Histoclear and
mounting in Depex.
Collagen was examined using a picro-sirius red stain. Picro-sirius red stains fibrotic
areas red and Fast Blue stains healthy tissue yellow (Williams et al., 1999). Sections
were fixed (as above), rinsed in distilled water and stained using Fast Blue
(prepared in magnesium borate buffer). Subsequently, sections were placed in
saturated picric acid for 5 minutes prior to staining with 0.1% (w/v) picro-sirius red
for 10 minutes. Sections were rinsed in picric alcohol, dehydrated, cleared and
mounted (as above).
Fifteen fields per section were selected and captured using a light microscope (Leica
labor lux5, Leica Microsystems, Milton Keynes, UK) and colour camera (CoolSNAP-
Pro, Meyer Instruments, Inc, Texas, UK). Myocardial collagen content was
quantified by a blinded observer using ImageJ software. Images were initially
converted to an 8-bit black and white image, where collagen appeared black. The
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black regions were detected and analysed by adjusting the threshold to ensure only
collagen areas were included (Figure 5.2). The collagen amount was expressed as a
percentage of the total area examined.
Step 1
Step 2
Step 3Figure 5.2: Sequence of collagen quantification
in ventricular sections
(Images were converted to an 8
. Picro-sirius red staining of collagen
(Magnification ×6.3)
-bit black and white image and black regions
quantified using ImageJ software)
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5.3 Results
5.3.1 In Vivo Cardiac Function
Table 5.1 shows the in vivo cardiac function in uraemic and control animals (in the
absence and presence of EPO treatment). The ventricular systolic pressures were
significantly elevated in uraemic hearts. Heart rate was unchanged and thus cardiac
RPP higher in uraemic animals (Table 5.1). Furthermore, in control animals, EPO
treatment resulted in a rise in ventricular systolic pressure relative to untreated
control hearts, an effect not seen in uraemic hearts.
dP/dtmax and dP/dtmin (Figure 5.3) were markedly higher in uraemic groups
compared with controls. Chronic EPO treatment had no impact on contractility in
control or uraemic hearts.
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Table 5.1: In vivo cardiac function at 12 weeks post-induction of uraemia
*p<0.05 vs. respective control Ŧ p<0.05 vs. untreated control
Max Pressure
(mmHg)
EDP
(mmHg)
LVDP
(mmHg)
RPP ×103
(mmHg.min-1)
Systolic Duration
(s)
Diastolic Duration
(s)
Control
(n=7)
- EPO 121 ±5 12 ±1 110 ±5 35 ±2 0.09 ±0.001 0.10 ±0.01
Uraemic
(n=6)
- EPO 158 ±6* 13 ±2 145 ±6* 49 ±4* 0.09 ±0.003 0.10 ±0.01
Control
(n=7)
+ EPO 135 ±3 Ŧ 13 ±1 122 ±3 Ŧ 40 ±2 0.09 ±0.001 0.10 ±0.01
Uraemic
(n=7)
+ EPO 154 ±6* 11 ±1 143 ±6* 48 ±3 0.09 ±0.002 0.09 ±0.01
Figure 5.3: In vivo
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Control (
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cardiac contractility at 12 weeks post-induction of uraemia
(*p<0.05 vs. respective control)
- Epo) Uraemic (- Epo)
n=6
Control (+ Epo)
n=7
Uraemic (+ Epo)
n=7
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*
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5.3.2 Cardiac Fibrosis
Figure 5.4 shows sections stained with picro-sirius red from the 4 groups of hearts.
The area of fibrosis was quantified (fibrotic area expressed as a percentage of the
total area) and results are given in Figure 5.5. Untreated and EPO treated uraemic
hearts exhibited increased fibrosis compared with controls. Chronic EPO
administration did not affect the quantity of fibrosis in either control or uraemic
hearts.
The types of fibrosis observed in uraemic hearts are provided in Figure 5.6.
Reparative, reactive perivascular (fibrosis around vessels), and reactive interstitial
fibrosis were observed in uraemic sections. Fibrosis in uraemic hearts appeared to
be predominantly reparative in nature, whereas in control animals, no reparative
fibrosis was observed.
Cardiac sections were also stained with haematoxylin and eosin, which revealed
little structural change between control and uraemic hearts (Figure 5.7).
Figure 5.4: Cardiac tissue stained using picro
b) EPO treated cont
a)
c)
-sirius red from a) control hearts
rol hearts (n=8), (c) uraemic hearts (n=6), (d
uraemic hearts (n=7) Magnification ×6.3
b)
d)
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Figure 5.5: Quantification of c
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n=7
- EPO
+ EPO
*
Figure 5.6: Sections from
uraemic hearts showing
types of fibrosis
Magnification ×6.3
PF perivascular fibrosis;
RF reparative fibrosis; I
interstitial reactive fibrosis
F
PF
a)
b)
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Figure 5.7: Cardiac tissue stained using Haematoxylin and Eosin from a) control
hearts (n=6), (b) EPO treated control hearts (n=8), (c) uraemic hearts (n=6), (d) EPO
treated uraemic hearts (n=7)
Magnification ×25
a) b)
c) d)
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5.4 Discussion
Uraemic hearts were characterised by increased fibrosis, which was unaffected by
EPO administration. In vivo assessment of cardiac function revealed a degree of
hyperfunction in uraemic animals, consistent with the compensatory phase of LVH.
These in vivo functional measurements parallel those observed in the in vitro
assessment in the perfused uraemic heart (Section 4.3.2).
5.4.1 In Vivo Cardiac Function
At 12 weeks, untreated and EPO treated uraemic animals had significantly elevated
LVDP and RPP. This is consistent with the hyperfunction observed in isolated
perfused hearts (Chapter 4) and is indicative of a compensatory phase of LVH. In
another study, assessment of in vivo cardiac function using a pressure-volume
Millar catheter, revealed improved systolic function in uraemic mice at 4, 6 and 8
weeks post-induction of uraemia (Kennedy et al., 2008). However, active and
passive relaxation times were prolonged in uraemic animals, highlighting diastolic
dysfunction (Kennedy et al., 2008). Other studies have observed impaired in vitro
cardiac function from 4 weeks uraemia (Raine et al., 1993). However, differing
severities of uraemia may impact on the observed cardiac phenotypic changes,
which may account for the difference in functional results obtained between
experimental studies. In CKD patients, cardiac dysfunction is also observed at early
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stages of uraemia (Pehrsson et al., 1984). However it is difficult to compare the
results obtained in this study to those observed in the clinical setting, due to
confounding coexisting conditions such as diabetes.
EPO treatment had no significant impact on in vivo cardiac function in uraemia. In
controls, EPO increased LVDP and cardiac contractility, in keeping with the
observed increase in blood pressure (Section 3.3.2). In this study, dysfunction was
not evident in uraemic hearts, therefore the protective role of EPO (in terms of
cardiac function) during uraemia could not be established. In non-uraemic models
of cardiac dysfunction, the role of EPO as a cardioprotectant has been confirmed
(Moon et al., 2005, Moon et al., 2003a, Shi et al., 2004, Wright et al., 2004).
Administration of EPO improved ejection fraction, ameliorated apoptosis and
reduced ventricular dysfunction after induction of MI in rats (Bullard and Yellon,
2005, Parsa et al., 2003). Interestingly, van der Meer et al. (2004) showed that EPO
treatment improved cardiac function in a rat model of post-MI heart failure even
when administered 3 weeks after coronary artery ligation. In support of these
findings, Li et al (2006) demonstrated that EPO treatment starting 6 weeks after
induction of MI, reduced fibrosis and improved cardiac function in a murine model
of chronic post-MI heart failure.
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5.4.2 Cardiac Fibrosis
Uraemic animals exhibited increased cardiac fibrosis compared with controls,
consistent with findings from other experimental studies of CKD, hypertension and
LVH (Mall et al., 1988, Zhai et al., 2008, Siedlecki et al., 2009, Varnava et al., 2000).
Cardiac fibrosis decreases ventricular compliance and impairs ventricular relaxation.
Indeed, left ventricular diastolic dysfunction is highly prevalent in haemodialysis
patients and can be detected in early stage CKD patients (Otsuka et al., 2009).
Interestingly, cardiac fibrosis in this study was not associated with impaired
function. Other experimental studies have shown that cardiac fibrosis was
associated with impaired relaxation and diastolic dysfunction despite preserved
LVDP and contractility (Merx et al., 2005). Using a pressure-volume catheter to
measure end-systolic and end-diastolic volume would have provided a more
comprehensive method for evaluating diastolic function and relaxation
(Stekelenburg-de Vos et al., 2005).
In addition to the deleterious effects of fibrosis on relaxation and ventricular
compliance, collagen has high electrical resistance. Deposition of collagen around
myocytes may thus cause a delay in the dissipation of the action potential, resulting
in ventricular arrhythmias (Saito et al., 2007). The deposition of collagen fibres
between capillaries and myocytes also leads to an increase in the oxygen diffusion
distance and contributes to oxygen starvation, enhancing the susceptibility of the
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uraemic heart to ischaemic injury (Dikow et al., 2004). In support of this, clinical
studies show that CKD patients have an increased risk of death following an acute
myocardial infarction, which correlates to the degree of renal dysfunction (Shlipak
et al., 2002, Wright et al., 2002).
Myocardial fibrosis can be divided into two main types, reparative and reactive. In
this study, both types of fibrosis were observed, with the majority predominantly
reparative in nature (Figure 5.6). In the uraemic heart, the increase in reparative
fibrosis may be to replace necrotic cells. Indeed, increased myocyte ‘drop-out’ has
been found in experimental uraemia most likely as a result of apoptosis or necrosis
(Amann et al., 2003). As uraemia progresses, it is feasible that interstitial collagen
increased accompanied by increased cross-linking forming a dense mesh of collagen
fibres contributing to impaired diastolic dysfunction.
In addition to experimental models, cardiac fibrosis has been observed in CKD
patients using the late gadolinium enhancement (LGE) method (Mark et al., 2006).
Gadolinium is an extra-cellular fluid tracer compound that can be detected using
magnetic resonance imaging; with expansion of ECM, gadolinium concentration
increases demonstrating myocardial fibrosis (Moon et al., 2003b). In addition,
cardiac fibrosis has also been confirmed in CKD patients at post-mortem (Mall et al.,
1990).
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The development of fibrosis during CKD is complex and incompletely understood.
Chronic overload, either by pressure or volume, may play a pivotal role.
Interestingly, in uraemic patients, cardiac fibrosis was significantly more
pronounced than in patients with diabetes or primary hypertension (Mall et al.,
1990). Furthermore, experimental studies have also shown that myocardial fibrosis
occurring during CKD is partly independent of blood pressure and LVH, suggesting a
specific pathophysiological cardiac alteration to uraemic cardiomyopathy (Mall et
al., 1990, Amann et al., 1998b).
Transforming growth factor-β (TGFβ) is a pleiotropic cytokine which can act as a
growth factor in the development of LVH and fibrosis (Koleganova et al., 2009a).
TGFβ promotes expression of ECM genes and also inhibits expression of ECM
degrading genes (Li et al., 2009a, Roberts et al., 1992). Transgenic mice over-
expressing TGFβ had significantly increased cardiac interstitial fibrosis compared
with wild-type animals (Rosenkranz et al., 2002). Furthermore, in mice subjected to
transverse aortic contrition, a time dependent increase in TGFβ was observed from
4 weeks post-surgery, correlating with the progressive rise in cardiac fibrosis (Li et
al., 2009a). TGFβ signalling is modulated by a class of proteins known as Smads.
Smad7 has an inhibitory effect on TGFβ signalling. Interestingly, a reduction in
Smad7 within the heart exacerbates fibrosis following myocardial infarction.
Furthermore, over-expression of Smad7 results in diminished collagen I and III
expression (Wang et al., 2002).
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CKD is associated with raised levels of angiotensin II which, in addition to its effect
on hypertension, has direct cellular actions including promoting cardiac fibrosis via
activation of TGFβ (Rosenkranz et al., 2002). Administration of ACE inhibitors and
ARBs reduce cardiac fibrosis in experimental uraemia and in CKD patients
(Tachikawa et al., 2003, Kurosawa et al., 2002). Interestingly, a sub-
antihypertensive dose of the ACE inhibitor, enalapril, improved fibrosis in the SHR
heart, highlighting a blood pressure independent effect of angiotensin II
(Piotrkowski et al., 2009). Furthermore, Angiotensin [1-7], known to counteract the
effects of angiotensin II, reduced TGFβ expression and cardiac interstitial fibrosis in
the 5/6 nephrectomised mouse (Li et al., 2009b). Experimental studies have shown
angiotensin II- mediated up-regulation of TGFβ to involve the ERK 1/2 pathway (Gao
et al., 2009). Indeed, treating isolated cardiac fibroblasts with the ERK inhibitor,
PD98059, blocked the angiotensin II induced increase in TGFβ and reduced collagen
I expression (Gao et al,. 2009). In the mammalian myocardium, two angiotensin II
receptors exist, AT1 and AT2 (Unger et al., 1996). The AT1 receptor is involved in
the development of fibrosis and inflammation whereas AT2 activation results in
apoptosis. Gao et al. (2009) showed that AT1 blockade prevented the angiotensin II
induced increase in TGFβ and collagen I expression in cardiac fibroblasts, whereas
AT2 blockade had no effect.
Experimental studies have shown that development of fibrosis is also associated
with low vitamin D levels and secondary hyperparathyroidism, which are frequent
complications in CKD (Smogorzewski et al., 1993). Subtotally nephrectomised rats
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did not develop cardiac fibrosis after removal of the parathyroid gland.
Interestingly, administering parathyroid hormone (PTH) to uraemic rats after
parathyroidectomy resulted in the development of cardiac fibrosis (Amann et al.,
1994). Furthermore, studies in experimental uraemia demonstrated a reduction in
PTH when treated with the active vitamin D compound, calcitriol, and this was
associated with a reduction in fibrosis (Koleganova et al., 2009b). Calcimimetic
agents, which decrease PTH by activating Ca2+ receptors, also reduced cardiac
fibrosis in experimental uraemia (Ogata et al., 2003). In parallel with these
observations, clinical studies have demonstrated improved survival in CKD patients
following administration of the active vitamin D analogue paricalcitol (Teng et al.,
2003). However, in contrast, Repo et al. (2007) showed that lowering of PTH with
paricalcitol not only did not prevent cardiac fibrosis but actually worsened it in
uraemic hearts (Repo et al., 2007). Thus, the situation remains unclear.
5.4.2.1 The Impact of EPO on Cardiac Fibrosis
In this study, EPO treatment had little effect on cardiac fibrosis in uraemia.
However, in experimental models of post- MI heart failure, EPO treatment reduced
interstitial fibrosis in non-infarcted regions and decreased collagen I and III mRNA
expression, which was associated with decreased expression of TGFβ (Nishiya et al.,
2006, Li et al., 2006). In an experimental model of diabetic kidney damage (db/db
mouse), TGFβ expression was reduced when mice were treated with a continuous
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EPO receptor activator (CERA) (Shushakova et al., 2009). Furthermore, in cultured
neonatal rat cardiomyocytes, EPO treatment attenuated the rise in TGFβ in
angiotensin II-induced hypertrophy (Wen et al., 2009).
EPO administration is associated with increased Stat 3 activation within the
myocardium (Li et al., 2006). Mice with cardiomyocyte specific Stat 3 deletion
exhibit significantly greater cardiac fibrosis (Jacoby et al., 2003). It is therefore
feasible that EPO mediated Stat 3 activation contributes to a reduction in cardiac
fibrosis observed in some animal models. Indeed, in an experimental model of iron
deficiency anaemia, the fibrosis observed at 20 weeks was accompanied by
decreased EPO levels and significantly reduced Stat 3 phosphorylation (Naito et al.,
2009). In contrast, Chan et al. (2007) showed that EPO prevents collagen
degradation via reduction in MMP expression leading to improved function post
ischaemia/ reperfusion by preserving the structural integrity of the myocardium
(Chan et al., 2007).
5.4.3 Conclusion
At 12 weeks, uraemic animals exhibit LVH, cardiac fibrosis and preserved cardiac
function. As uraemia progresses further, it is feasible that a pathophysiological
phenotype will ensue, including accelerated interstitial fibrosis alongside a
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reduction in capillary density thereby contributing to decompensation and heart
failure.
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Chapter 6: Mitochondrial Function and Protein Expression
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6.1 Introduction
The uraemic heart is characterised by a depleted energy reserve (Ogimoto et al.,
2003, Raine et al., 1993) and metabolic remodelling (chapter 4), which contribute to
heart failure (Ingwall and Weiss, 2004). Mitochondria are pivotal in providing the
heart with energy, in the form of ATP. Furthermore, mitochondria play a key role in
the initiation of apoptosis, via the intrinsic pathway and release of cytochrome c
(section 1.6.2.1), thereby controlling a tight balance between life (i.e. energy
production) and cell death (Gustafsson and Gottlieb, 2008).
6.1.1 Electron Transport Chain (ETC)
Acetyl-CoA, a product of pyruvate oxidation and β-oxidation, enters the TCA cycle
generating NADH and FADH2, which, in a series of oxidation-reduction reactions,
transfer electrons (e-) through a chain of inner mitochondrial membrane enzyme
complexes known as the ETC (Figure 6.1). NADH and FADH2 donate electrons to
complex I (NADH dehydrogenase) and complex II (succinate dehydrogenase) of the
ETC respectively. Electrons are then carried to complex III (cytochrome bc1
complex) using the mobile electron transporter coenzyme Q (or ubiquinone), and
then to complex IV (cytochrome c oxidase) using a second mobile electron carrier,
cytochrome c (Lesnefsky et al., 2001). At complex IV, 2 electrons, along with 2
hydrogen ions combine with the final electron acceptor, oxygen, forming water.
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At complex I, III and IV of the ETC, the transfer of electrons is coupled with the
movement of hydrogen ions (H+) or protons, from the matrix side to the cytosolic
side of the inner mitochondrial membrane (Figure 6.1). The energy potential from
the proton gradient, known as the protonmotive force (∆p) is used by ATP synthase 
(F1F0 ATP synthase) to drive ATP synthesis from ADP and inorganic phosphate (Pi),
coupled to proton flux toward the mitochondrial matrix. Chemiosmotic theory is
essential to explain the coupling between ETC and ATP synthesis (Equation 7)
(Mitchell, 1961).
Figure 6.1: Schematic representation of the electron transport chain (ETC)
(NADH, nicotinamideadenine dinucleotide (reduced); FADH2, flavin-
adenine dinucleotide (reduced); Q, coenzyme Q; Cyt c, cytochrome c)
(adapted from(Moncada and Erusalimsky, 2002)
166 | P a g e
∆݌= ∆߮ − 2.3൬ܴܶ
ܨ
൰∆݌ܪ
6.1.2 Reactive Oxygen Species (ROS) Production
ROS are free radicals with an unpaired electron in their outermost shell. They are
highly reactive and damaging to DNA, lipids and proteins. The primary source of
ROS formation is the mitochondrial ETC as a result of electron leakage,
predominantly from complex I and complex III (Ambrosio et al., 1993). The major
mitochondrial-produced ROS is the superoxide anion (O2˙
-), formed by the partial
reduction of oxygen. Under normal conditions, up to 1-5% of consumed oxygen
forms superoxide, which can be scavenged by a number of enzymes, including
manganese superoxide dismutase (MnSOD), which converts superoxide to
hydrogen peroxide (H2O2) and then to water (Giulivi et al., 1995).
Uncoupled or impaired mitochondrial function and altered ETC complex activities
increase the production of ROS, exceeding the antioxidant defence capacity.
Mitochondria are producers of, and targets of, ROS-induced damage. ROS can
initiate apoptosis by mediating the opening of non-specific mitochondrial
Equation 7: Protonmotive Force (Mitchell, 1961)
(∆߮ membrane potential; R gas constant; T
absolute temperature; F Faradays constant
membrane pores, including MPTP (Section 1.6.2.1), thereby collapsing the
membrane potential, resulting in further ROS formation from the ETC (Kowaltowski
et al., 2001). This positive feedback mechanism is known as ROS-induced ROS-
release (RIRR) (Zorov et al., 2000) (Figure 6.2).
gen
permeabilisation
mitochondrial damage
ROS formation
APOPTOSIS
cytochrome c release
caspase 3 activationFigure 6.2: Mitochondrial ROSeration andmitochondrial membraneind167 | P a g e
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6.1.3 Mitochondrial Function in Uraemia
Few studies have investigated cardiac mitochondrial function in uraemia. Using a
genomic approach, Granata et al. (2009) observed alterations in a number of genes
involved in mitochondrial respiration in CKD patients compared with healthy
controls. Furthermore, alterations in the expression of genes encoding
mitochondrial ETC proteins have been observed in the spontaneously hypertensive
rat (SHR) heart (Piotrkowski et al., 2009). Mitochondrial function has also been
examined in models of LVH and heart failure. As LVH is present in up to 75% of
haemodialysis patients, parallels could be drawn from these studies on the
hypertrophied heart (Foley et al., 1995). Experimental hypertrophic
cardiomyopathy (HCM) was associated with a decrease in state 3 respiration along
with reductions in complex I and IV activities (Lucas et al., 2003). Interestingly,
studies on the failing heart have shown both unchanged (Rennison et al. 2009) and
decreased (Rosca et al., 2009) mitochondrial function. Heather et al. (2009)
observed reduced mitochondrial respiration rates in the failing heart only when the
ejection fraction was markedly reduced (</=45%), whereas in hearts exhibiting mild
functional impairment, mitochondrial function was preserved.
Alterations in myocardial mitochondrial function during uraemia may compromise
ATP production and increase ROS formation leading to apoptotic cell death. In
support of this, enhanced ROS generation has been observed in patients with CKD
and haemodialysis patients (Dounousi et al., 2006, Granata et al., 2009, Morena et
al., 2005). Furthermore, cardiomyocyte apoptosis was exacerbated in rats following
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5/6 nephrectomy (Rodriguez-Ayala et al., 2006). Importantly, in addition to reduced
mitochondrial respiration and ROS formation, ATP synthesis may also be
compromised by altered expression of key proteins involved in substrate
metabolism. PPARα is the primary transcription factor responsible for the
regulation of fatty acid metabolism, controlling the expression of proteins including
MCAD and CD36. Down-regulation of these proteins may be responsible for the
decrease in fatty acid oxidation observed during uraemia, and thus contribute to
energy starvation.
6.1.4 Objectives
In this chapter, the combined impact of uraemia and chronic EPO administration on
in vitro mitochondrial function was assessed. Specific aims were
 To determine the impact of uraemia and chronic EPO treatment on cellular
respiration in isolated cardiac mitochondria.
 To examine the expression of PPARα and CD36 proteins in untreated and
EPO treated control and uraemic ventricular tissue
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6.2 Methods
6.2.1 Mitochondrial Respiration
Uraemia was induced surgically in male Sprague-Dawley rats via a one-stage 5/6th
nephrectomy (section 2.2.1). Animals were divided into 4 experimental groups
 Control animals + saline (- EPO)
 Uraemic animals + saline (- EPO)
 Control animals + EPO
 Uraemic animals + EPO
EPO was administered twice a week for 2 weeks prior to experiments at a dose of
30 µg/Kg (section 3.3.2).
Cardiac mitochondria were isolated from the 4 groups of rats at 9 and 12 weeks
post-induction of uraemia, and ADP-stimulated respiration determined using a
Clark-type electrode, as described in Section 2.2.7.
A Clark-type electrode consists of a silver anode and platinum cathode connected
via an electrolyte solution (KCl). The sample chamber is separated from the
electrode compartment by a Teflon membrane, which prevents the electrolyte
solution mixing with the sample (Figure 6.3). When a constant polarising voltage
(0.6 V) is held between the two electrodes, the platinum electrode becomes
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negative relative to the silver electrode. Oxygen diffuses through the membrane
from the sample chamber and is reduced to water at the cathode. The reduction of
oxygen generates a current which is directly proportional to the oxygen
concentration. The current can then be amplified and converted to a digital signal
for analysis (Robinson, 2001).
Figure 6.3: Clark- type electrode
(from Rank Brothers manual www.rankbrothers.co.uk/download/digioxy.pdf)
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Oxygen consumption of mitochondrial preparations (0.4 mg protein/ ml), was
determined in the presence of the following substrates
 glutamate (5 mM) and malate (1 mM) (Complex I)
 palmitoyl carnitine (20 µM) and malate (2 mM)
 succinate (5 mM) and rotenone (1 µM) (Complex II)
ADP (0.2 mM) was added to stimulate state 3 respiration. State 4 respiration was
monitored after exhaustion of ADP.
6.2.2 Protein Expression
PAGE (PolyAcrylamide Gel Electrophoresis), using a 3% stacking gel and 10%
running gel, and western blotting, was used to determine protein expression of
PPARα, CD36 and Actin (as a control), in 12 week untreated and EPO treated
control and uraemic ventricular tissue (section 2.2.8). The optimum antibody
dilutions and suppliers are given in Table 2.3.
I would like to thank Mrs Kathleen Bulmer for her assistance with the Western
Blotting
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6.3 Results
6.3.1 Mitochondrial Respiration
Mitochondria were isolated from 9 and 12 week untreated and EPO treated control
and uraemic hearts. At both stages of uraemia, the mitochondrial protein yield was
comparable between all 4 groups, suggesting that the mitochondrial content was
not altered by 9 or 12 weeks uraemia (Table 6.1).
At 9 weeks uraemia, mitochondrial respiration rates were determined in the
presence of complex I substrates, glutamate and malate (representative traces
given in Figure 6.4) and complex II substrates, succinate and rotenone.
To confirm state 3 (ADP-stimulated) respiration in the presence of glutamate and
malate, rotenone (a specific complex I inhibitor) was added which significantly
reduced oxygen consumption (Figure 6.5). When rotenone was added in the
presence of succinate, respiration was not inhibited as succinate drives the electron
transport chain through complex II, by-passing complex I.
Table 6.1: Myocardial mitochondrial protein yields at 12 weeks uraemia
Protein concentration mg/ml
Control
(n=4)
Uraemic
(n=4/5)
- EPO 5.63 ±0.69 4.65 ±0.44
+ EPO 5.11 ±0.27 5.04 ±0.74
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Figure 6.5: State 3 respiration in the presence of rotenone
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After 9 weeks uraemia, the rates of state 3 and 4 respiration was comparable
between all 4 groups in the presence of complex I and complex II substrates (Table
6.2 a and b). Similarly, the ADP:O ratio was similar in all groups.
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Table 6.2: Mitochondrial respiration at 9 weeks post-induction of uraemia
a) Complex I substrates (glutamate and malate)
State 3
Respiration
(nmol /min/ mg
protein)
State 4
Respiration
(nmol /min/ mg
protein)
Respiratory
Control Index
(RCI)
ADP:O
Control
(n=2)
- EPO 170.2 ±40.4 32.8 ±18.4 7.2 ±3.1 0.50 ±0.03
Uraemic
(n=2)
- EPO 140.3 ±38.1 24.9 ±17.6 9.2 ±5.0 0.47 ±0.02
Control
(n=2)
+ EPO 204.6 ±22.0 39.6 ±7.7 5.3 ±0.5 0.53 ±0.03
Uraemic
(n=2)
+ EPO 194.3 ±44.6 50.5 ±15.3 3.9 ±0.3 0.53 ±0.01
b) Complex II substrates (succinate + rotenone)
State 3
Respiration
(nmol /min/ mg
protein)
State 4
Respiration
(nmol /min/ mg
protein)
Respiratory
Control Index
(RCI)
ADP:O
Control
(n=2)
- EPO 187.1 ±7.1 26.2 ±16.8 12.4 ±8.2 0.54 ±0.02
Uraemic
(n=2)
- EPO 149.2 ±20.4 23.4 ±15.0 9.9 ±5.4 0.52 ±0.05
Control
(n=2)
+ EPO 203.1 ±12.2 44.7 ±7.5 4.6 ±0.5 0.54 ±0.04
Uraemic
(n=2)
+ EPO 229.1 ±99.3 32.9 ±6.5 6.9 ±2.0 0.54 ±0.02
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By 12 weeks uraemia, no differences were observed in the rates of mitochondrial
respiration or the ADP:O ratio in all 4 groups (Table 6.3 a, b and c and Figure 6.6)
Table 6.3: Mitochondrial respiration at 12 weeks post-induction of uraemia
a) Complex I substrates (glutamate and malate)
State 3
Respiration
(nmol /min/ mg
protein)
State 4
Respiration
(nmol /min/ mg
protein)
Respiratory
Control Index
(RCI)
ADP:O
Control
(n=3)
- EPO 127.7 ±12.0 25.2 ±1.9 5.9 ±1.1 0.46 ±0.06
Uraemic
(n=4)
- EPO 122.5 ±2.7 21.7 ±8.4 15.0 ±6.7 0.46 ±0.02
Control
(n=5)
+ EPO 128.2 ±11.1 25.4 ±6.4 7.6 ±2.9 0.48 ±0.01
Uraemic
(n=3)
+ EPO 125.7 ±15.0 30.8 ±2.6 4.2 ±0.8 0.48 ±0.04
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b) Complex II substrates (succinate + rotenone)
State 3
Respiration
(nmol /min/ mg
protein)
State 4
Respiration
(nmol /min/ mg
protein)
Respiratory
Control
Index (RCI)
ADP:O
Control
(n=3)
- EPO 178.6 ±38.4 22.8 ±9.8 13.8 ±7.9 0.50 ±0.02
Uraemic
(n=3)
- EPO 191.8 ±21.4 35.4 ±6.5 6.1 ±1.7 0.52 ±0.02
Control
(n=5)
+ EPO 154.7 ±22.7 22.2 ±3.1 7.8 ±1.9 0.48 ±0.02
Uraemic
(n=3)
+ EPO 111.2 ±2.9 20.0 ±2.9 5.8 ±1.6 0.52 ±0.02
c) Palmitoyl carnitine + malate
State 3
Respiration
(nmol /min/ mg
protein)
State 4
Respiration
(nmol /min/ mg
protein)
Respiratory
Control Index
(RCI)
ADP:O
Control
(n=2)
- EPO 146.7 ±38.1 17.8 ±12.2 14.2 ±5.7 0.50 ±0.02
Uraemic
(n=2)
- EPO 104.7 ±7.0 10.4 ±5.0 13.9 ±6.5 0.48 ±0.01
Control
(n=1)
+ EPO 111.3 10 12.2 0.46
Uraemic
(n=1)
+ EPO 110.6 9.9 11.3 0.46
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6.3.2 Metabolic Protein Expression
PPARα and CD36 protein expression were determined in ventricular tissue and
normalised to actin.
At 12 weeks uraemia, PPARα and CD36 expression did not significantly differ in
untreated and EPO treated control and uraemic hearts (Figures 6.7 and 6.8).
Figure 6.7: Cardiac
Figure 6.8: Cardiac
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6.4 Discussion
Mitochondrial respiration rates were similar in control and uraemic hearts at 9 and
12 weeks post-induction of uraemia and were unaffected by chronic EPO
treatment. This highlights unchanged efficiency under in vitro conditions. These
results are consistent with observations from the perfused heart showing
unchanged efficiency in uraemic animals. Expression of key proteins controlling
fatty acid metabolism were unchanged by uraemia or chronic EPO administration.
6.4.1 Mitochondrial Respiration
At 9 and 12 weeks uraemia, myocardial mitochondrial respiration was unaltered in
control and uraemic hearts, consistent with a compensatory phase of LVH.
Furthermore, uraemia was not associated with a reduction in mitochondrial density
as evidenced by unaltered mitochondrial yields and comparable citrate synthase
activities (Section 4.3.4). State 3 and state 4 respiration rates, observed here, are
comparable with previous studies in cardiac mitochondria (Lucas et al., 2003).
Little work has been undertaken with regards to the impact of experimental
uraemia on myocardial mitochondrial respiration. In a recent study, DNA analysis
on peripheral blood mononuclear cells revealed differences in 44 genes involved in
mitochondrial respiration in CKD patients. Specifically, a 65% reduction in complex
IV activity (determined by following the rate of ferrocytochrome c oxidation) was
184 | P a g e
observed in uraemic and haemodialysis patients compared with healthy controls
(Granata et al., 2009). Whether these alterations also occur in myocardial
mitochondria during CKD has yet to be determined.
Alterations in ETC complex activities and impaired myocardial mitochondrial
function during uraemia would lead to elevated ROS production, potentially
exceeding the antioxidant capacity of the heart, resulting in oxidative stress. At high
levels, ROS initiates necrosis via membrane lipid peroxidation; at low levels, ROS
can induce apoptosis (Lennon et al., 1991). Indeed, antioxidant therapy effectively
reduced apoptosis in cultured cells (Kelso et al., 2001). Furthermore, down-
regulation of the antioxidant defence system is associated with increased apoptosis
(Fujii et al., 2006).
The exact mechanisms behind ROS-induced apoptosis have not been fully
elucidated. ROS initiates the release of cytochrome c and caspase 3 activation,
possibly via modulation of mitochondrial membrane permeability (MPT) (Higuchi et
al., 1998). The impact of ROS on MPT has been mainly ascribed to the effects on the
MPT pore (MPTP) (Zorov et al., 2000). MPTP is a non-specific mitochondrial
membrane pore, which, when open, allows the free movement of ions and solutes
(<1500 daltons) into the mitochondria causing swelling and rupture of the outer
mitochondrial membrane resulting in release of pro-apoptotic factors including
cytochrome c. Cytochrome c is a potent activator of the caspase cascade, leading to
apoptotic cell death. Indeed, blocking MPTP with agents such as cyclosporin A and
bongkrekic acid prevents apoptosis (Zamzami et al., 1996).
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The structure of MPTP remains in debate (Grimm and Brdiczka, 2007, Halestrap,
2009). It was originally thought to consist of three principal components, the
adenine nucleotide translocator (ANT), the voltage-dependent anion channel
(VDAC), and cyclophilin D (CycD). However, using knockout animal models, it has
recently been shown that ANT is more likely a regulatory component (Kokoszka et
al., 2004). Interestingly, in CycD knockout mice, the loss of membrane potential
with H2O2 was abolished, suggesting that CycD may be the site for ROS-induced
MPTP opening (Baines et al., 2005).
ROS production is also a characteristic of heart failure, possibly as a result of
impaired mitochondrial respiration and/or structural abnormalities (Ide et al., 1999,
Ide et al., 2001, Sharov et al., 2000). In experimental heart failure induced by aortic
constriction, myocardial mitochondrial respiration was significantly impaired as
evidenced by decreased state 3 respiration rates (Bugger et al., 2009). Moreover,
reduced complex III and IV activities have been observed in patients with
congestive heart failure (Buchwald et al., 1990, Jarreta et al., 2000). In contrast, in
the post-MI failing rat heart, mitochondrial respiration rates were not impaired
(O'Shea et al., 2009). Furthermore, Wistar rats with heart failure induced by
coronary artery ligation, showed no alterations in state 3 respiration when using
glutamate or succinate. However, with palmitoyl carnitine as a substrate, state 3
respiration was elevated in mitochondria from failing rat hearts compared with
controls (Rennison et al., 2008). Interestingly, this effect was only seen in the
subsarcolemmal (SSM) population not in interfibrillar mitochondria (IFM).
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Separating the two populations of mitochondria in this study may have unmasked
subtle differences in respiratory activities between control and uraemic hearts.
Conflicting results have also been found with regard to mitochondrial function in
LVH. In a mouse model of hypertrophic cardiomyopathy (genetically induced by
mutating cardiac troponin T), mitochondrial respiration was preserved (Lucas et al.,
2003). However, mice with hypertrophic cardiomyopathy induced by the myosin
heavy chain gene mutation, demonstrated impaired state 3 respiration compared
with wild-type animals (Lucas et al., 2003).
It is feasible that during compensated hypertrophy, mitochondrial function is
preserved. With cardiac dysfunction and transition to heart failure, mitochondrial
respiration may become compromised. In support of this, Heather et al. (2009)
observed no differences in state 3 or state 4 respiration rates in failing hearts with
an ejection fraction >45%. Interestingly, with severe functional deterioration post-
MI (ejection fraction </=45%) mitochondrial function was compromised (Heather et
al., 2009). These studies suggest that mitochondrial dysfunction might be a
consequence, rather than a cause of impaired cardiac function, which is consistent
with the results from this study. With progression of uraemia and deteriorating
cardiac function, mitochondrial function may potentially become compromised.
ADP:O ratios were similar in all 4 groups and unchanged at 9 or 12 weeks uraemia,
although values were substantially lower than those observed in previous studies
(Heather et al., 2009, O'Shea et al., 2009).
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The ADP:O ratio is essentially mediated by the coupling of electron transport to ATP
synthesis. Uncoupling of oxygen consumption with ATP synthesis frequently
increases state 4 respiration, i.e. ADP-independent respiration. State 4 respiration
was not raised in this study, suggesting well coupled mitochondria. The addition of
uncouplers such as 2,4-Dinitrophenol (2,4-DNP) and carbonyl cyanide-p-
trifluoromethoxyphenylhydrazone (FCCP), to the mitochondrial preparation could
confirm the degree of uncoupling; well coupled mitochondria would exhibit a rapid
burst of oxygen consumption, greater than that observed during state 3 respiration.
Uncouplers prevent the link between electron transfer and ATP synthesis without
affecting electron transport itself. Protons are carried across the mitochondrial
membrane by uncouplers thus dissipating the proton gradient. The degree of
uncoupling within mitochondria can be mediated via expression of uncoupling
proteins (UCPs). The predominant form of UCP within the heart is UCP3. In
transgenic mice over expressing UCP3, state 4 respiration was significantly
increased along with markedly higher oxygen consumption in skeletal muscle
(Clapham et al., 2000). Interestingly, elevated plasma free fatty acid concentrations
have been shown to correlate with UCP expression (Murray et al., 2004). In
particular, cardiac UCP3 levels are augmented by free fatty acids in a PPARα
dependent manner (Young et al., 2001b). Free fatty acids are increased in patients
with CKD and could potentially contribute to raised mitochondrial UCP expression
resulting in uncoupling (Gadegbeku et al., 2004). However, in this study, a similar
degree of uncoupling was observed between control and uraemic cardiac
mitochondria in vitro. In response to challenges such as increased free fatty acids,
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it is feasible that mitochondria from uraemic hearts may become uncoupled
resulting in compromised mitochondrial function and ROS generation leading to
apoptosis.
6.4.2 Metabolic Protein Expression
Twelve weeks uraemia had little effect on PPARα protein expression (Figure 6.7)
despite the observed decrease in fatty acid oxidation. Only few studies have
assessed PPARα in the uraemic heart. Mori et al. (2007) observed a 44% reduction
in liver PPARα mRNA at 10 weeks post-induction of uraemia (Mori et al., 2007). In
the hypertrophied heart, experimental studies have observed unchanged (Duda et
al., 2007) and decreased (Akki et al., 2008) PPARα mRNA. Importantly, mRNA levels
may not always reflect protein expression due to post-transcriptional modification.
Furthermore, changes in protein levels may not necessarily relate to altered
activity. The activity of PPARα is modulated by the heterodimeric receptor RXR, and
the co-factor PGC-1α, each of which may affect the expression of mRNAs (Vega et
al., 2000). Interestingly, in an experimental model of chronic heart failure, PGC-1α
was down-regulated (Garnier et al., 2003). Decreased PGC-1α reduces the
transcription of FAO related proteins, and may account for the diminished
palmitate oxidation observed in this model.
CD36 expression was reduced in untreated uraemic hearts compared with
respective controls (Figure 6.8). In an experimental model of angiotensin II-induced
hypertension, CD36 mRNA expression was significantly decreased (Yamashita et al.,
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2008). Given that uraemia is associated with hypertension and elevated angiotensin
II, it is feasible that this could account for the reduction in CD36 protein expression
observed in this model. Conversely, in a rat model of hypertrophic cardiomyopathy,
cardiac CD36 expression was significantly up-regulated compared with hearts from
wild-type animals (Luedde et al., 2009). However, the decrease in CD36 may be a
direct result of enhanced angiotensin II rather than hypertrophy per se.
6.4.2.1 Impact of EPO on Protein Expression
Chronic EPO administration did not significantly impact on the protein expression of
PPARα or CD36 (Figure 6.8). There has been little research into the effect of EPO on
key metabolic protein expression. PPARα, which regulates CD36 expression, can be
modified post-transcriptionally via the ERK/ MAPK pathways, leading to reduced
activity without alterations in expression (Barger et al., 2000). Thus, activation of
these pathways may decrease PPARα activity, in turn resulting in decreased
expression of PPARα-regulated proteins including CD36 (Barger et al., 2000).
Interestingly, EPO has been shown to activate the ERK and MAPK pathways in the
reperfused heart, as part of the reperfusion injury salvage kinase pathway (RISK)
(Bullard et al., 2005, Chan et al., 2007, Rafiee et al., 2005). Therefore, could
potentially reduce PPARα activity and decrease the expression of protins which
PPARα regulates including CD36. Furthermore, a number of experimental studies
have shown EPO to activate the Akt pathway (Bahlmann et al., 2004, Li et al., 2006).
Cook et al. (2002) observed a decrease in PGC1α mRNA in mice over expressing Akt.
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It is therefore feasible that EPO may decrease CD36 by reducing PGC1α therefore
decreasing PPARα activity, however this was not observed in this study.
6.4.3 Conclusion
PPARα and CD35 protein expression were unchanged in uraemic hearts. Despite
LVH and fibrosis observed by 12 weeks uraemia, mitochondrial function was not
compromised during uraemia. It is feasible that with prolonged uraemia and
increased challenges to the heart, mitochondrial dysfunction will ensue, leading to
ROS production, apoptosis and instigating the transition to heart failure.
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Chapter 7: Discussion and Future Work
192 | P a g e
7.1 Discussion
Surgical induction of uraemia via a single 5/6th nephrectomy resulted in elevated
serum creatinine and anaemia from 3 weeks post-surgery. By 12 weeks uraemia,
animals exhibited worsening kidney function, anaemia, hypertension and cardiac
hypertrophy, characteristic features of CKD. At this stage of uraemia, there was no
evidence of cardiac or mitochondrial dysfunction suggesting a compensatory phase
of LVH.
7.1.1 Extent of Kidney Dysfunction
In this study, kidney function was assessed by analysing serum creatinine
concentration. Unfortunately, serum creatinine is also affected by other factors
including muscle mass. As uraemia progresses, some animals lose muscle mass,
which may falsely lower serum creatinine resulting in underestimated kidney
dysfunction (Lindeman, 1993). In CKD patients, determining glomerular filtration
rate (GFR) provides a more accurate measure of kidney function, and is frequently
estimated using the MDRD (modification of diet in renal disease) equation, which
takes into consideration a number of variables in addition to serum creatinine
including age, sex and race (Levey et al., 1999). In rats, collecting urine over a 24 h
period would allow estimation of GFR by measurement of creatinine clearance
(Perrone et al., 1992). Furthermore, urine could also be analysed for other markers
of kidney dysfunction including microalbuminuria.
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The extent of kidney damage in this model of uraemia was moderate, with mild
renal fibrosis, which parallels early stages of CKD (Figure 7.1). This allowed the
cardiac alterations in uraemia to be investigated prior to onset of cardiac
dysfunction. Such cardiac changes may be responsible for the onset of heart failure
and thus potentially provide useful therapeutic targets or diagnostic markers.
Inducing uraemia via surgical resection of the upper and lower kidney poles would
have created more severe kidney damage consistent with end stage renal disease
(ESRD). Furthermore, infarcting the kidney by ligating the renal vessels would have
also produced more advanced renal dysfunction, however, the degree of damage is
less consistent (Liu et al., 2003). Producing a more severe model of kidney disease
may have induced pathophysiological cardiac changes resulting in impaired cardiac
function, and would have therefore allowed the cardioprotective nature of EPO (in
terms of improving function) to be further assessed.
7.1.2 EPO
Chronic EP
However,
uraemic anFigure 7.1: Kidney sections stained using Masson’s trichrome stain
from a) control and b) uraemic remnant kidney
(Pictures kindly provided by Dr Chee Kay Cheung)a) b)194 | P a g e
Treatment
O administration did not impact on the progression of renal dysfunction.
it improved haematocrit and induced partial regression of hypertrophy in
imals despite continued hypertension.
×40 magnification
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Approximately, 90% of haemodialysis patients in the UK receive EPO (Richardson et
al., 2007), which improves anaemia and increases quality of life. However, the
direct cellular impact of EPO in uraemic cardiomyopathy is incompletely
understood. Acute and chronic EPO administration improve cardiac function and
delay the onset of heart failure in a number of experimental models (Li et al., 2006,
van der Meer et al., 2005). Interestingly however, clinical trials have provided
conflicting results regarding the efficacy of EPO in the uraemic heart and the future
of EPO as a cardioprotectant remains uncertain (Hayat, 2009, Pfeffer et al., 2009).
EPO has adverse effects including hypertension, the most frequent complication
associated with EPO therapy (Lee et al., 2007). Moreover, EPO increases production
and reactivity of platelets, thereby raising the risk of cardiovascular events
(Stohlawetz et al., 2000). Although EPO does improve quality of life for CKD patients
by treating anaemia, it is feasible that any direct beneficial effects on the heart are
cancelled out by the complications associated with EPO treatment resulting in no
improvement in survival rates in CKD patients.
EPO has been shown to be cardioprotective in animal models of heart failure (Li et
al., 2006, van der Meer et al., 2005, Westenbrink et al., 2007). However, effects of
EPO on the heart could be related to elevated erythropoiesis and consequently,
increased oxygen delivery to the myocardium. In this regard, in experimental
uraemia, it is difficult to dissociate direct cardiac effects of chronic EPO
administration from the improvement in haematocrit. Specifically, the EPO-induced
regression of LVH could result from the amelioration of anaemia, or the EPO-
mediated activation of anti-hypertrophic signalling pathways, or a combination of
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both. Recent studies using low-dose EPO treatment have shown cardioprotection
post-MI without a rise in haematocrit (Lipsic et al., 2008). Furthermore,
carbamylated erythropoietin (CEPO), which does not stimulate erythropoiesis,
maintains its cardioprotective properties despite no change in haematocrit
(Fiordaliso et al., 2005, Moon et al., 2006). Administration of EPO without the rise in
haematocrit would allow the dissociation of direct cardiac actions from the anti-
anaemic effects in uraemic cardiomyopathy.
7.2 Future Work
By 12 weeks uraemia, hearts exhibited LVH with preserved function. It is feasible
that, although cardiac function is not compromised at this stage of uraemia, with
increased stresses to the heart, dysfunction may ensue. Indeed, recent studies from
this laboratory have shown that post-ischaemia, uraemic hearts have a poorer
recovery during reperfusion (Figure 7.2). This is consistent with the findings of
Dikow et al. (2004), showing reduced ischaemic tolerance post-MI. Moreover, the
death rate following acute MI is much higher in CKD patients compared with the
normal population (Shlipak et al., 2002). Even mild renal insufficiency was
associated with an increased risk of death following MI, and risk increases with
worsening renal function (Wright et al., 2002).
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During ischaemia/reperfusion, the addition of insulin in the perfusion medium is
known to be cardioprotective, reducing cell death and improving cardiac function
via activation of the RISK pathway (Jonassen et al., 2000). Uraemia is characterised
by insulin resistance (DeFronzo et al., 1981). Indeed, studies from this laboratory
have demonstrated that insulin had little impact on the recovery of function in
uraemic hearts during reperfusion (Figure 7.2). It would be interesting to examine
the impact of EPO in uraemic hearts during ischaemia/reperfusion. EPO, like insulin,
has been shown to improve function post-ischaemia (Bullard et al., 2005, Cai and
Semenza, 2004). However, it is unknown whether EPO has the same protective
effects during ischaemia/reperfusion in uraemic hearts. It is feasible that since EPO
may exert its effects through the same pathway as insulin (via activation of the RISK
pathway), the effects of EPO in ischaemia/reperfusion may also be blunted in the
same way as insulin protection is lost.
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Hearts may also be stressed in vitro by increasing cardiac work, which can be
achieved by pacing hearts at a higher rate or raising the buffer calcium
concentration. In support of this, McMahon et al. (2002) observed impaired
relaxation of isolated uraemic cardiomyocytes only in the presence of 4 mM
calcium.
Figure 7.2: Recovery of rate pressure product (RPP) during reperfusion
CNI Control no insulin; CI Control with insulin; UNI Uraemic no insulin;
UI Uraemic with insulin
(all groups n=5)
§ p<0.05 vs. control no insulin # p<0.05 vs. uraemic with insulin * p<0.05 vs. uraemic no insulin
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In vivo, following induction of uraemia, hearts could be subjected to MI, by ligating
the coronary artery. Again, this may expose differences in the functional capacity
between uraemic and control hearts. Furthermore, it would be interesting, if
uraemic hearts did exhibit impaired function during increased challenges, if this
could be improved with EPO treatment.
In this model of uraemia, metabolic remodelling was observed at 6 and 12 weeks
consistent with the onset of LVH. Interestingly, PPARα expression, which, in models
of LVH, is typically down-regulated, was unchanged (Lehman et al., 2000). PPARα is
regulated by the co-factor PGC1α (Finck and Kelly, 2006). In experimental models of
heart failure, expression of PGC1α is diminished, which may account for the
observed reduction in fatty acid oxidation (Garnier et al., 2003). PGC1α also plays a
key role in mitochondrial biogenesis. Indeed, in PGC1α-/- mice, expression of genes
involved in FAO, electron transport chain and oxidative phosphorylation are
decreased, along with a reduction in mitochondrial density (Lehman et al., 2008). It
would be interesting to determine expression of PGC1α in the uraemic heart. It is
feasible that decreased PGC1α may account for the change in substrate use from
fatty acids to glucose and although in vitro mitochondrial function was preserved at
this stage, with progression of uraemia, the reduction in PGC1α may eventually lead
to compromised mitochondrial function, impaired ATP synthesis and ROS
production, thereby initiating the onset of heart failure.
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The switch in substrate usage may represent a beneficial adaptation to sustain
function in LVH given that glucose is more oxygen efficient than fatty acids (van
Bilsen et al., 2009). It would therefore be interesting to prevent this remodelling
during uraemia and determine the impact this has on cardiac function. Young et al.
(2001) found that preventing the decrease in fatty acid oxidation by reactivating
PPARα worsened cardiac function in LVH, an affect which may also occur in the
uraemic heart.
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